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ABSTRACT

Allan, Mikaela L. M.S., Purdue University, August 2014. Role of resveratrol metabolites
in adipose function. Major Professor: Kee-Hong Kim.

The rise in obesity rate has drastically increased over the last few decades and has
quickly grown into a worldwide epidemic. Large increases in visceral adipose tissue
accumulation increase risk for metabolic disorders including insulin resistance, type 2
diabetes, and cardiovascular diseases. Currently, increased levels of circulating nonesterified fatty acids (NEFA) have been suggested to be the mediator linking obesity and
type 2 diabetes. Studies identifying ways to alleviate mobilization of NEFA in adipose
tissue via dietary phytochemicals may useful as a therapeutic approach. Despite the
established benefits of resveratrol in health and in the development of obesity, the role of
resveratrol metabolites in lipid metabolism remains unknown.
The objectives of this study were to determine the role of resveratrol metabolites
in adipose function with a focus on the effect in lipolysis and lipogenesis. Resveratrol
metabolite, piceatannol, previously demonstrated its role as an antilipolytic agent through
the suppression of lipolysis via protein degradation of adipose triglyceride lipase (ATGL)
and comparative gene identification-58 (CGI-58). We hypothesized other resveratrol
metabolites exhibit similar effects in modulating the lipolysis process. In our study, we
examined several resveratrol metabolites and identified trans-   -trimethoxy
resveratrol (TMR) having ability to suppress lipolysis in basal and stimulated conditions
in mature murine adipocytes at non-cytotoxic levels. Upon further mechanistic studies,
TMR at 50 µM reduces ATGL and CGI-58 protein expression with greatest efficacy in
an acute, three hour treatment. mRNA expression analysis displayed that TMR may also
play a role in transcriptionally regulating lipolytic genes. Additionally, we investigated

xvii
the role of TMR in lipogenesis in maturing preadipocytes. Although TMR did not display
significant reductions in lipid accumulation during lipogenesis, gene expression profiling
indicates it may induce transcriptional remodeling of adipocyte function. Of interest,
TMR upregulates expression of genes involved in mitochondria function suggesting
increased catabolic processes, thermogenesis, and potential enhanced capacity for energy
expenditure during development. Collectively, our study provides evidence that TMR, a
resveratrol metabolite, might have a therapeutic potential in attenuating adiposity and its
associated metabolic disorders.
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CHAPTER 1. REVIEW OF THE LITERATURE

1.1

Introduction

The rise in obesity rate has drastically increased over the last 30 years and has
quickly grown in to worldwide epidemic (Rosen and Spiegelman 2006; Van Gaal et al.
2006). Obesity, a disease of excess body fat, has attracted more attention due to the
influence it has on regulation of overall energy homeostasis and coordinated responses
(Rosen and Spiegelman 2006). Individuals with large visceral (central) adipose tissue
deposition have elevated risk for metabolic disorders, morbidity, and mortality (Van Gaal
et al. 2006). The large energy imbalance seen in obesity can be attributed to a variety of
different factors including environmental, genetic, and metabolic function of central
tissues (Kim et al. 2013).
Currently, investigations identifying the role of phytochemicals on human health
is being done, however there is less work examining the modulation obesity via action by
phytochemicals (Kim et al. 2013). The role of natural bioactive components have been
shown to have a wide range of action in signaling pathways and cellular functions (Kim
et al. 2013). In this review of the literature, several molecular pathways involved in
adipose function and lipid metabolism are outlined in regards to the development of
obesity and its associated metabolic disorders. Additionally, dietary compounds,
specifically resveratrol metabolites, are defined and examined as a potential therapeutic
strategy in specific adipocyte functions related to the development of obesity and its
associated diseases. Taken together, this review offers a central background of
information for further understanding concerning the selected research goals and
objectives of our study.
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1.2

Obesity

Obesity is defined as an excess accumulation of body fat to the ration of lean
body mass. Obesity is determined with a numerical value of body mass index (BMI) of
30 or greater (CDC 2012). BMI is calculated with a formula based on weight in
kilograms divided the height of adult in meters (CDC 2011). Although obesity is
commonly associated with extreme body weight, it is a heterogeneous group of
conditions which have compounded by multiple causes and determined by genetics,
environmental factors, energy intake and expenditure, and culture (Kopelman 2000).
Until recently, obesity has only been considered a metabolic condition, and primarily
isolated to developed western civilization. However within the 20th century, global
increases in body weight have been on the rise in developing countries as well (Caballero
2007). Changes in global food systems have caused a complex issues resulting in
overnutrition and the promotion of obesity meanwhile nearly one billion people are
malnourished (Swinburn et al.). The World Health Organization estimated that in 2008,
1.4 billion adults were overweight and 500 million obese (WHO 2013). Over the last two
decades, the rapid rise in obesity rate in the United States has drastically increased to an
astonishing level of more than one-third the population , 35.7% , with 17% of adolescents
and children, who are obese (Ogden et al. 2014). The development of obesity and
increased adiposity is coupled with physiological changes in function and in the
distribution of adipose tissue. With contribution by obesogenic factors, obesity expansion
is caused by increased intake of energy-dense foods, reduced physical activity, with
increases in sedentary lifestyles. The imbalance between energy intake and energy
expenditure over time results in positive energy balance with increased energy stores, as
adipose mass, and weight gain (Bleich et al. 2011).
The American Medical Association recently recognized obesity as a disease
which now requires medical interventions and is altering the way the medical community
treats the complex issue and other chronic illness related to obesity (Breymaier 2013).
Obesity is associated with many other metabolic disorders including cardiovascular
disease, type 2 diabetes, inflammation, and certain cancers (Despres and Lemieux 2006).
Also widely seen with excess fat accumulation is a composite of metabolic syndrome; a
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combination of health issues that is largely seen with visceral obesity which is not
exclusive to hyperlipidemia, insulin resistance, high blood pressure, and hypertension
(Despres and Lemieux 2006). Moreover, obesity has also been reported as the underlying
cause of sleep apnoea and sleep-related strokes which can lead to pulmonary
hypertension, heart and respiratory failure (Kopelman 2000). Not only does the obesity
rate cause a threat to global health, there is causation of severe financial implications. A
conservative estimate for US national healthcare expenditures was estimated at $3.5
trillion in 2012, and that number is projected to increase to $5 trillion by 2020 (CMS
2010; 2014) with $150 billion attributed solely to obesity (Finkelstein et al. 2009).
Defining strategies to alleviate not only the medical affliction of the obesity epidemic, but
also the financial spending magnitude are imperative. It has been reported that modest
weight loss can help to reduce risk factors for obesity associated diseases (BenMenachem 2007; NIH 2005). Nonetheless, of the 51% of Americans who desire to lose
weight, less than half are actively working to shed pounds (Brown 2013). Therefore,
identifying therapeutic approaches is critical to help prevent or treat obesity and its
associated metabolic disorders.

1.3

Adipose biology

Adipocytes play a critical role in whole body energy homeostasis and metabolism.
Adipose tissue stores fatty acids (FA) in the efficient form of triglycerides via
esterification to glycerol, and in times of excess energy expenditure or an energy shortage,
it releases them into circulation (Galic et al. 2010). There are two types of adipose tissue:
white and brown adipose tissue (BAT), each containing specific physiological roles
(Mohamed-Ali et al. 1998). White adipose tissue (WAT) is the primary adipose tissue
depot in humans and is largely characterized by unilocular adipocytes with single lipid
inclusion used for storage and mobilization (Ahima and Flier 2000). Excess energy is
stored as triacylglycerides in adipose tissue and can increase in tissue volume through
increases in size of an adipocyte lipid droplet (LD), hypertrophy, and in number of
adipocytes, hyperplasia, or both (Spiegelman and Flier 1996). In adults, most expansion
of adipocytes occurs from increased LD size in adipocytes due to tight regulation of the
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number of fat cells, holding constant throughout adulthood in lean and obese individuals
(Spalding et al. 2008). Although, changes in body weight are primarily due to increase
ad  

      

           



 

hyperplasia, and induces the conversion of preadipocytes to adipocytes. Therefore, after
losing body weight, it can be particularly hard to maintain a lean weight due to the
constant number of adipocyte cells (Arner and Spalding 2010).
Adipose tissue is a complex, active, and essential metabolic endocrine organ
comprised of two-thirds adipocytes, and one-third connective tissue, nerve tissue,
stromovascular cells, and immune cells. The traditional idea of adipose tissue solely used
for energy storage is no longer relevant, as it has been widely studied for its metabolism
and endocrine functions (Kershaw and Flier 2004). Adipose tissue is responsible for
secreting endocrine, paracrine, and autocrine signals which include a range of proteins
termed adipokines and lipoprotein regulators; such as leptin, tumor necrosis factor-
(TNF-

   

-6 (IL-6), adiponectin, resistin, lipoprotein lipase, cholesterol ester

transfer protein, and apoliporotein E (Mohamed-Ali et al. 1998). Adipokines participate
in a variety of metabolic action via physiological processes which include inflammation
and immune health (Lago et al. 2007). Overall, excess accumulation of adipose tissue
poses a public health threat as whole body health and metabolism is affected and
negatively effecting longevity and reduceing life expectancy (Olshansky et al. 2005).
Moreover, identifying therapeutic strategies to specific adipose tissue targets may have
large potential in curbing obesity and its associated syndromes.

1.4

Adipogenesis

Adipocytes are derived from multipotent mesenchymal stem cells which allow
them to have a two-step process in becoming mature adipocytes (Rosen and MacDougald
2006). This process begins with commitment to the adipocyte lineage followed by
induction of terminal differentiation (Otto and Lane 2005). The first step of determination
results in a preadipocyte that has lost its ability to differentiate into other cell lines.
Widely used and accepted as a model for adipocyte biology include 3T3-L1 cells,
originally clonally isolated from Swiss 3T3 mouse embryos (Green and Kehinde 1975;
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Green and Meuth 1974; Gregoire et al. 1998). Preadipocytes are morphologically similar
to that of fibroblasts and expansion of preadipocytes via hyperplasia occurs until
confluence, when appropriate induction of differentiation causes the cell to acquire
characteristics of mature adipocytes (Rosen and MacDougald 2006). In order for the
differentiation process to occur, there are several steps that are completed, including
development and growth arrest, allowance of mitogenic and adipogenic signals, and
biochemical transformation, shown in Figure 1.1. Induction of differentiation in 3T3-L1
cell culture requires a cocktail of hormonal stimulation that is given to cells comprising
of dexamethasone (DEX), methylisobuthylxanthine (MIX), and insulin. Mitotic clonal
expansion (MCE) occurs unique to non-primary preadipocytes which permits one or two
more rounds of DNA replication. Terminal differentiation is accompanied by a
transcriptional cascade which creates a distinctive spherical shape and accumulates LDs
(Gregoire 2001; Gregoire et al. 1998; Otto and Lane 2005).

1.4.1

Preadipocyte development, growth arrest, and differentiation

In order to differentiate, preadipose cell lines which have proliferated and display
a fibroblastic morphology are required to reach a level of confluence (Gregoire et al.
1998; Hausman et al. 1980; Reichert and Eick 1999). The physical contact of cells results
in growth arrest at which point preadipocyte cells withdraw from the cell cycle to
undergo adipose conversion. It has been noted that cell to cell contact is not a sole
requirement for this conversion into adipocytes, as it has been observed that cells plated
at low density still maintain and go through differentiation (Gregoire 2001; Gregoire et al.
1998). Pre-confluent proliferation and growth arrest are necessary for preadipocytes to
experience the appropriate morphological and distinct gene expression before their
transformation to adipocytes.
Subsequent to growth arrest, preadipocytes must receive signals to further their
development through differentiation which allow them to make specific biochemical
alterations. CCAAT/enh    
   

       

                

specific adipocyte genes (Gregoire et al. 1998). Nonetheless, normal preadipocytes

-
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maintain high levels of preadipocyte factor-1 (pref-1), C/EBP homologous protein
(CHOP-10), and GATA transcription factors until they are down-regulated upon
differentiation (Mei et al. 2002; Tang and Lane 2000; Tong et al. 2000). Pref-1 is a
transmembrane protein inhibitor of adipogenesis (Mei et al. 2002), and is highly abundant
in the stromal-vascular fraction of preadipocytes yet absent in mature adipocytes (Smas et
al. 1999). Growth arrested preadipocytes express CHOP-10 which is responsible for

  
              
                     (Ron and
Habener 1992; Tang and Lane 2000). GATA-2 and GATA-3 transcription factors bind
specifically to DNA sequences, and are found in high levels in WAT and solely
expressed in preadipocytes (Tong et al. 2000). Inherent expression of both represses
differentiation in adipocytes, however with induction of differentiation these factors are
down-regulated (Tong et al. 2005).
In order for these transcription factors to be expressed, cells are stimulated to
differentiate with a standard adipogenic mixture supplemented to fetal bovine serum
(FBS) containing medium including the glucocorticoid DEX, cyclic adenosine
monophosphate (cAMP)-phosphodiesterase inhibitor MIX, and a high dose of insulin
(Macdougald and Lane 1995; Rosen and Spiegelman 2000; Sadowski et al. 1992). It is
important to note that different cell models require diverse cocktails for the induction of
differentiation due to the nature of the reagents used (Gregoire 2001). In 3T3-L1 cell
linage culture, this standard mix is used to induce the cells to begin their transformation
into adipocytes. As mentioned, DEX is a synthetic glucocorticoid responsible for the

           (Hajduch et al. 1995; Wu et al. 1996),
meanwhile blunting the expression of Pref-1 (Smas et al. 1999). MIX heightens
differentiation by increasing cAMP levels and through the downstream actions of the
cAMP pathway (Pantoja et al. 2008)    

  (Cao et al. 1991).

Insulin is required for efficient differentiation of adipocytes because it not only increases
the amount of lipid accumulation, but also it reduces apoptotic activity through insulinlike growth factor-I (IGF-I) (Kiess and Gallaher 1998). Insulin action in differentiation is
via cross-activation of IGF-I receptors inducing downstream signaling, stimulating many
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adipogenic effects (Rosen and Spiegelman 2000). Taken together, MIX, DEX, and
insulin create favorable conditions for 3T3-L1 cells to undergo morphological and
metabolic changes during differentiation to allow for cytoplasmic lipid accumulation
(Zhou et al. 1992).

1.4.2

Mitotic clonal expansion

Once differentiation has occurred in growth arrested cells at G0/G1 cycle, they are
able to return to the cell cycle for one or two more rounds of DNA replication and cell
doubling; a progression known as MCE (Tang et al. 2003). MCE occurs approximately
24 hours after differentiation has been induced and is thought to be a necessary process to
allow for the unwinding of DNA, subsequently allowing access for transcription factors
to begin appropriate regulatory responses for the development of a mature adipocyte
phenotype (Ntambi and Kim 2000). This DNA replication during mitosis also alters the
promoter control elements helping to activate regulatory genes which initiate
differentiation (Cornelius et al. 1994). However, whether MCE is truly required for
differentiation has been deemed controversial; yet studies have identified evidence
showing it is a prerequisite and that certain proteins acting as checkpoints for mitosis are
important in the regulation of adipogenesis (Otto and Lane 2005; Rosen and MacDougald
2006). Insulin was able to induce MCE solely, similarly to when 3T3-L1 cells are
induced into the differentiation process through an adipogenic cocktail (Qiu et al. 2001).
Certain growth proteins are essential during clonal expansion and include retinoblastoma
proteins such as pRB, p107, p130 each which bind to E2F/DP resulting in an inactivation
specific transcriptional growth factors (Gregoire et al. 1998). When there is inhibition of
MCE in 3T3-L1 cells, differentiation of preadipocytes has been shown to be blocked
(Nam et al. 2008). To note, cell division in primary adipocytes stemming from human
adipose tissue is not a requirement when proceeding through differentiation. It is
suggested that these specific type of cells have previously experienced the necessary cell
divisions in vivo, and are already in the late stage of adipocyte development (Entenmann
and Hauner 1996).
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1.4.3

Adipogenic transcriptional cascade

Necessary communication of extracellular signals by differentiating adipocytes to
the nucleus give rise to the introduction of a transcriptional cascade (Gregoire et al. 1998).

 
    

The coordination of gene-expression events including the expression of PPA

         



differentiation (Rosen and MacDougald 2006). These factors trigger terminal
differentiation and commitment of cells to the adipocyte lineage (Dani 1999). These
changes compound a result of morphological changes and developed fat droplets.

1.4.3.1 PPAR family

       

   -dependent transcription factors

that bind the ligand of receptors leading to activation of a target gene (Kersten et al.
2000). PPARs behave similar to hormone receptors in which they bind the promoter
region of a specific gene and form a heterodimer with retinoid X receptor (RXR), which
results in activation responses in transcription when bound to the ligand hormone
(Kersten et al. 2000)

               

adipose, brown adipose, liver, kidney, heart, and skeletal muscle (Kersten et al. 2000).

           

 !

 " 

 # 

are transcribed from the same gene only with different splicing and promoters (Otto and

 "    
             
     $  %        
  

Lane 2005)

and its early binding in the differentiation process is required for the development of
mature adipocytes (Spiegelman and Flier 1996; Tontonoz et al. 1994).

    

in transcription of genes in FA uptake, storage, and specifically adipocyte P2 (aP2),
lipoprotein lipase, acyl-coenzyme A synthase and others (Otto and Lane 2005). It has
also been demonstrated that expression of P

            

ability to go through adipogenesis (Wu et al. 1999b), as well as having no formation of
WAT and little amounts of BAT (Mohamed-Ali et al. 1998). Animals that contain natural

                 
(Mohamed-Ali et al. 1998) & ''            
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adipose tissue mass and mouse embryonic fibroblasts resulted in impaired adipogenesis.

 

                

however they maintained normal levels of adipose mass and morphology (Rosen and
MacDougald 2006). 

           
                     

of its regulatory transcriptional activity (Spiegelman and Flier 1996; Tontonoz et al.
1994). In 3T3-L1 cell culture model, its activity has been aptly demonstrated and shown
to increase with insulin (Hu et al. 1995). Additionally, overexpression of the adipokine,

                 (Attie and Scherer
2009).

1.4.3.2 C/EBP family
The transcription factor family of C/EBPs contains a basic luecine zipper domain,
allowing activation via homo-and hetero-dimerization (Gregoire et al. 1998). This
dimerization is a criterion for DNA-binding (Otto and Lane 2005). For the regulation of

           !  "  #    $
(Otto and Lane 2005). Upon hormonal stimulated differentiation in vitro  "  
 #           %&   '(&   (Yeh et al.
1995). They are early regulators in the program of preadipocyte differentiation
demonstrated by their ability to accelerate adipogenesis with protein overexpression,
specifically in 3T3-L1 cells (Otto and Lane 2005). 

", though rapidly expressed

after differentiation stimulators, does not possess the DNA binding ability until its
phosphorylation occurs and it loses its association with CHOP-10, thus gaining DNA
binding activity (Tang et al. 2004)) *

  "      

   

can participate in DNA binding after a 12 to 16 hour lag phase, simultaneously with the
S-phase of MCE (Tang and Lane 1999). Subsequent to DNA binding 

"   
                 $    
initiate the transcription activation (Zhang et al. 2004). The transcriptional activators

   

  $          

  

adipogenic genes and terminal differentiation action (Fajas et al. 1999). It is also been
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day two of differentiation to approximately day five after differentiation induction
(Ntambi and Kim 2000). To note, embryonic fibroblasts which did not contain both
 

               

adipocytes (Tanaka et al. 1997). Furthermore, a dominant-negative C/EBP compound,
     

termed A

 !"        

         #

   (Zhang et al. 2004).

         ose tissue due to its ability to
induce adipocyte genes directly (Rosen and MacDougald 2006)$

    

contain C/EBP regulatory elements, and thereby can act as a positive feedback loop that,
            
(Tang et al. 2004)$

  "%&  

                

metabolism, due to its modulation of adipocyte genes and encoding proteins specific to
adipose tissue (Darlington et al. 1995)$ '   
  

(       $

     

            

in liver, and in white and brown adipose tissues (Wang et al. 1995). In 3T3-L1
preadipocytes, C/E          
differentiate into mature adipocytes; demonstrating its important role in modulating
differentiation (Freytag et al. 1994)$ !   

 necessary for differentiation, it

has been reported as sufficient to activate growth arrested cells without use of hormonal
stimulation (Lin and Lane 1994)$

         i-mitotic activity,

thus early expression of this gene would inhibit preadipocytes from entering MCE, a
necessary requirement for 3T3-L1 differentiation (Otto and Lane 2005). Importantly,
PPAR& 

                

responses to maintain terminal differentiation (Spiegelman 1998).

1.4.4

Terminal differentiation

Terminal differentiation is a state in which adipocytes have largely increased in de
novo lipogenesis and are sensitive to insulin (Gregoire et al. 1998). Cells are no longer
participating in the cell cycle and lose their capacity to proliferate; although after
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differentiation, preadipocytes may be able to de-differentiate and re-enter mitosis
(Cornelius et al. 1994). Nonetheless, once cells have surpassed the GD point, they have
become fully committed to terminal differentiation (Otto and Lane 2005). Observable
changes take place with increased lipogenesis and LD formation. Mature adipocytes have
lost their preadipocyte fibroblastic characteristics and appear spherical with the
acquisition of biochemical and morphological traits of adipocytes (Macdougald and Lane
1995). Cells have also increased in protein levels related to lipid metabolism and
enhanced expression of adipose tissue specific products, such as aP2 and FA binding
protein (FABP). Furthermore, lipogenic enzymes and adipokines are highly expressed
including leptin, adiponectin, and resistin (Gregoire et al. 1998; Otto and Lane 2005).

1.5

Lipogenesis

Triacylglycerides (TAG) are made up of a glycerol backbone esterified with three
FA chains. TAG synthesis activity in WAT is an imperative factor for determination of
adipose tissue mass and the release of non-esterified FA (NEFA). As seen in fasting rats,
approximately 57% of newly hydrolyzed FA were recirculated for TAG synthesis (Wang
et al. 2008). Although FA mainly come from the diet, 1-2% are made in adipose tissue
itself (Wang et al. 2008). The carbon movement from glucose to FA is highly regulated
by lipogenesis and involves a series of enzymatic reactions (Ameer et al. 2014). During
FA synthesis, the first step includes a series of conversion reactions of citrate to acetylCoA by ATP-citrate lyase (ACL) (Ameer et al. 2014). Carbons coming from acetyl-CoA
are added to a growing chain of FA. The key rate limiting step is ATP dependent on
acetyl-CoA carboxylation to malonyl-CoA carboxylase 1 by acetyl-CoA carboxylase 1
(ACC1) (Gathercole et al. 2013). Malonyl-CoA is then transformed by multiple steps into
a 16 carbon FA, palmitate, by fatty acid synthase (FAS), the major enzyme accounting
for FA biogenesis (Zaidi et al. 2013). Further reactions lead to the production of
complicated FA originating from palmitate, resulting in de novo lipogenesis (DNL)
products of palmitate, and small amounts of stearate and shorter FA (Ameer et al. 2014).
Once FA have been generated by DNL, they are converted into substrates for
TAG formation by becoming saturated and transformed into monounsaturated FA
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(MUFAs) by stearoyl-CoA desaturase 1 (SCD1). SCD1 has preference to convert
saturated stearate and palmitate to their MUFAs oleate and palmitoleate, respectively.
SCD1 is a rate limiting reaction and its desaturase activity has been proposed to reduce
FA oxidation and stimulate DNL (Hulver et al. 2005). Biogenesis of TAG is a series of
esterification of FA moieties that are consecutively added to a glycerol backbone (Farese
and Walther 2009). The acylation of a glycerol-3-phosphate and the first FA occurs by
glycerol-3-phophate acyltransferase (GPAT) and the second by diacylglycerol
acyltransferase (DGAT) yielding phosphatidic acid (PA), which is then dephosphorylated
to produce diacylglycerol (DAG) (Gathercole et al. 2013; Kuerschner et al. 2008). DAG,
by a third acylation, then becomes TAG, but could be used as a prerequisite for
phospholipids. DGAT2, which is highly associated with adipocytes, is localized to the
endoplasmic reticulum (ER) and is responsible for the catalyzed reaction into TAG
(Kuerschner et al. 2008). Of the enzymes which are involved in TAG synthesis, they are
commonly found in the ER as well as the mitochondria, or in mitochondrial-associated
membranes and have different isoforms. Newly generated TAG have been suggested to
be at large to go into an associated lipid bilayer and locating to cytosolic LD, or to cells
which secrete TAG (Yen et al. 2008).
The biogenesis of LDs are defined as the initial accumulation of neutral lipids
tightly connected at the ER (Digel et al. 2010). LDs are linked to a wide variety of
functions which include lipid storage, energy and membrane formation, and protein
degradation. LD synthesis occurs de novo and are generated in the ER (Walther and
Farese 2012). LDs are primarily comprised of an organic phase of TAG and sterol esters
in the core, yet other neutral lipids are present such as free cholesterol and retinol ester
(Thiele and Spandl 2008). However the majority of the volume in adipocytes is TAG.
The initial step is followed a gathering of proteins and increased lipid synthesis to create
a globular LD. LDs have been observed in contact with the ER when formed and the
specific membrane associated proteins moved between the two complexes (Walther and
Farese 2012). In periods of excess energy, TAG need to be stored in LD and allowance
for growth in LD requires local coordinated TAG synthesis or a translocation from the
ER. This involves large amounts of TAG being located to its core (Farese and Walther
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2009). LD droplet formation include ER budding which allows LD to grow from the ER
bilayer and then bud off (Walther and Farese 2012). The main thought is that TAG
biosynthesis is done between the leaflets of the ER membrane, prior to budding off and
forming a LD. It was demonstrated that TAG is synthesized near the surface of the LD,
accordingly indicated LDs grow by influx. Thus LDs can grow in size with droplet to
droplet fusion and via increasing TAG levels (Kuerschner et al. 2008).
In adipose tissue, all the major lipogenic enzymes are present, however only low
levels have been observed compared to rodents (Gathercole et al. 2013). The low levels
of ACL, which produces cytosolic acetyl-CoA for FA synthesis, is suggested to be reason
DNL in adipose tissue accounts for a small percentage of lipid generation (Gathercole et
al. 2013; Wang et al. 2008). Nonetheless, DNL in vitro is regulated partly by hormones
and the dysregulation of the lipogenic pathway can cause disruption to overall lipid
metabolism and homeostasis (Ameer et al. 2014).

1.6

Lipolysis

LDs are a critical and active organelle found in the intracellular cytoplasm of
many cells. Previously, adipose tissue and LDs were considered only inert storage
locations for excess fat (Ahmadian et al. 2009). However in recent years, LD biology has
been an increasing interest due to studies identifying proteins and mechanistic pathways
specific to LDs and represent a progressive area in cell biology (Farese and Walther 2009;
Walther and Farese 2012). Within the core of the LD, TAG, which are highly
hydrophobic, reduced and concentrated, are used for storing energy, occupying much of
the space in the cytoplasm (Farese and Walther 2009). Surrounding the LD is a
phospholipid monolayer covered with proteins functioning to stabilize and regulate
(Brasaemle 2007).
The mobilization of the stored energy stems from lipolysis; the hydrolysis of TAG
into NEFA and a single glycerol backbone (Zechner et al. 2012) as shown in Figure 1.2.
Lipolysis is an absolute prerequisite for cellular uptake and of release of FA to and from
the bloodstream, first observed by Whitehead in 1909 (Whitehead 1909). This catabolic
process allows for NEFA to be released during fasting, in times of metabolic need, as
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well as when TAGs are in a surplus amount (Zechner et al. 2012). Nonetheless, the
process of lipolysis is an intricate phenomenon which orchestrates the use of cellular
lipases, plasma membrane transporters, FA binding proteins, and LD associated proteins
(Langin 2006a). This mobilization of NEFA from adipose tissue via lipolysis, can be
released to enter the bloodstream and

  



 





-oxidation and

further for ATP formation. NEFA may also be transported to the liver in order to be used
as substrates for ketogenesis, and glycerol for gluconeogenesis (Ahmadian et al. 2010).

1.6.1

Lipolytic cascade

Lipolysis occurs in periods of increased energy demand or expenditure, and is
activated by hormones (Zimmermann et al. 2004). The concentration of NEFA is highly
regulated between a balance of triglyceride hydrolysis and NEFA esterification (Langin
2006b). Hydrolysis points occur at the primary and secondary ester bonds between the
FA and the glycerol backbone (Zimmermann et al. 2004). Adipocyte lipolysis occurs in a
meticulous order of events and in a regulated fashion, with each step utilizing a different
enzyme; sequentially adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL),
and monoglyceride lipase (MGL) (Ahmadian et al. 2009; Walther and Farese 2012;
Zechner et al. 2012). ATGL performing the initial cleavage of the first FA is the rate
limiting step in which it transforms the TAG to form a diacylglyceride (DAG) and a
NEFA. The second lipase, HSL, is a multifunctioning enzyme in that it has the capacity
to hydrolyze TAG, DAG, and monoacylglyeride (MAG); its cleavage of FA from the
acylesters contain a breadth (Lass et al. 2011). In fact, HSL was formerly thought to be
the rate limiting lipase in TAG hydrolysis (Duncan et al. 2007), however, Haemmerle
demonstrated through HSL knockout mice a shift in composition of fat: rather than
accumulating TAG, KO mice increased in DAG levels, observably showing that HSL is
primarily responsible for DAG hydrolysis (Haemmerle et al. 2002). Lastly, MGL
removes the final FA, freeing the last NEFA and glycerol (Duncan et al. 2007; Lass et al.
2011). This simple explanation for describing the lipolysis process is tightly regulated by
a highly complex system of signals and mechanisms.
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Increased levels of NEFA and glycerol in serum to be used as oxidative substrates
are products of stimulated lipolysis (Duncan et al. 2007). Catecholamines are the major
regulators in fasting induced lipolysis and are considered the starting point in the
metabolic pathway that modulates TAG hydrolysis and NEFA release (Duncan et al.
2007). Catecholamines are able to impact lipolysis once they bind to different
adrenoceptor

  

1-3

and

1-2,

each linked to a G-protein (Jocken and Blaak

2008). Norepinephrine, a catecholamine, binds to -adrenergic receptors, on the
adipocyte plasma membrane, which is coupled to a G-  

  

                

most active (Barbe et al. 1996; Jocken and Blaak 2008). The G-

 

 s,

3

is

then

sends a signal to adenylyl cyclase (AC) which then activates the production of cAMP
(Duncan et al. 2007). The increase in cAMP intracellular levels leads to the activation of
a cAMP dependent protein kinase (PKA) (Carmen and Víctor 2006). Once cAMP binds
PKA, this results in the controlling subunits to disassociate with the catalytically active
stretch, thus increasing activity of the complex (Kim et al. 2005). This activation of PKA
results in the phosphorylation of HSL and perilipin, a LD surface protein, and to further
the catalysis of TAG to release NEFA and glycerol (Carmen and Víctor 2006) (Jocken
and Blaak 2008). In addition, in the fasted state high levels of glucocorticoids also
increase ATGL transcription and generate a signaling cascade (Villena et al. 2004). There
are other signaling pathways which also induce lipolytic reactions in 3T3-L1 cells
including protein kinase C and its stimulation by phorbol ester PMA in a dependent
mitogen-activated protein kinase (MAPKs) and independent MAPK pathway (Carmen
and Víctor 2006) 

        

2-adrenoceptors

that are coupled to

inhibitory G-proteins (Gi). These Gis will inactive AC, thus reducing cAMP levels and
muting PKA activity (Jocken and Blaak 2008).
During a fed state, insulin acts as an antilipolytic agent via a regulatory pathway
which involves both cAMP dependent and independent pathways (Duncan et al. 2007). In
adipocytes, the cAMP dependent cascade involves insulin binding to its receptor which
transmits a signal resulting in activation of phosphodiesterase 3B by phosphorylation, in
turn degrading cAMP levels (Ahmadian et al. 2010). This reduction of cAMP levels
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relieves PKA from activation and blunting the phosphorylation mediated activity of HSL
and perilipin (Duncan et al. 2007). The cAMP independent modulating pathway by
insulin is through the stimulating phosphorylation of protein phosphatase-1(PP-1)
causing an alteration in its regulatory subunit. Activating phosphorylation of PP-1 results
in the dephosphorylation and inactivation of HSL, reducing the lipolytic rate (Duncan et
al. 2007; Razani et al. 1999). Insulin also has action in regulating the expression of
ATGL; insulin has been shown in 3T3-L1 cells to down-regulate ATGL possibly through
FoxO1 (Ahmadian et al. 2010; Kershaw et al. 2006).
The physiological relevance of the controlling pathways of lipid metabolism is
critical due to the volume of fat that is predominately found in adipose tissue (Jocken and
Blaak 2008). Dysregulation of lipolysis and lipid metabolism can lead to severe
physiological consequences. Specifically in a high fat diet-induced obesogenic state,
there is increased basal lipolysis resulting in increased levels of circulating NEFA
(Gaidhu et al. 2010). Defective regulation of lipolysis leads to excessive NEFA
accumulation in visceral adipose tissue, and is highly correlated to insulin resistance
which can result in impairment of the this hormone to act as an antilipolytic agent
(Gaidhu et al. 2010). Overall, alternations in the regulation of this catabolic process can
induce physiological impacts that can lead to defective mechanisms and lead to metabolic
disorders.

1.6.2

ATGL

In 2004, three different groups identified a novel lipolytic enzyme which was
responsible for TAG hydrolysis, and each gave the lipase a different name including
ATGL (Zimmermann et al. 2004), desnutrin (Villena et al. 2004), and phospholipase A2
(Jenkins et al. 2004). In the scope of this review, ATGL will be the name utilized. ATGL
is a 54 kDa protein that has an N-terminal domain similar to patatin, a plant acyl
hydrolase, which encompasses its catalytic activity that cleaves at the primary ester bond
at sn-1(3) position (Duncan et al. 2007; Lass et al. 2011; Walther and Farese 2012).
ATGL is tightly associated with the LD in differentiated 3T3-L1 cells and maintains a
hydrophobic region for binding to the LD (Duncan et al. 2007); loss of this domain
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results in loss of intracellular activity because of its inability to locate and bind the LD
(Zechner et al. 2012). ATGL is considered to be the major lipase in adipose tissue
lipolysis with its high substrate specificity to TAG (Ahmadian et al. 2010), showing
minimal activity toward other lipids including DAG, MAG, cholesterylesters or
retinylesters (Lass et al. 2006; Lass et al. 2011). The localization of ATGL has been
determined, with the majority of ATGL locating in the cytoplasm (approximately 50%),
yet a portion of it is found to be tightly associated to the LD, around 10% (Zimmermann
et al. 2004). This amount of ATGL localized with the LD is not affected by the
stimulation of lipolysis, with Zimmermann observing the co-localization to the LD in
3T3-L1 cells (Zimmermann et al. 2004). In energy demand, increased levels of ATGL
translocate from the cytosol to the surface of the LD upon activation (Bezaire et al. 2009).
When ATGL is genetically altered in vivo, NEFA release by lipolysis was reduced
greater than 75% in ATGL-deficient mice (Haemmerle et al. 2006; Haemmerle et al.
2002).
ATGL expression and enzymatic activity is tightly regulated. ATGL requires an
activator protein which markedly increases its activity known as comparative gene
identification -58 (CGI-    



 ain containing protein 5 (ABHD5)

(Zimmermann et al. 2009) (Lass et al. 2011). Through interaction of ATGL and CGI-58,
maximum stimulation is seen at equal concentrations of both proteins (Lass et al. 2006).
Studi        
    

  

         

      

  !"-58 interaction also

occurs. The C-terminal end of the ATGL includes its regulatory function and location of
its LD interaction (Lass et al. 2011). The activation of ATGL by CGI-58 is necessary for
lipolytic action and acts independently of HSL (Bezaire et al. 2009). Another key
regulator for ATGL involves its interaction with perilipins; proteins which are highly
associated with LD surface, in which many are phosphorylated by AMP-dependent PKA
upon lipolytic stimulation (Clifford et al. 1998). Studies identifying the complex system
of how ATGL is activated as the initial step in lipolysis suggest CGI-58 and perilipins
engage the enzyme and mediate ATGLs LD targeting and hydrolysis of TAG (Walther
and Farese 2012). Hydrolytic activity of ATGL in fat cell lipolysis, in both the basal and
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hormone stimulated conditions, to proceed is necessary and maintains as the first step in
the sequential regulation of lipolysis (Lafontan and Langin 2009).
Studies observed ATGL ablation in 3T3-L1 cells showed that with compromised
lipolysis, cells were not able to compensate, even with the presence of other lipases
(Duncan et al. 2007). ATGL-null mice have extreme TAG accumulation in the heart
which resulted in premature heart failure (Brasaemle 2007), as well as reduced lipolysis
which lead to fat deposition in many tissues, including fat, liver, muscle, kidney, spleen,
and lung tissues (Lass et al. 2011). This has also been demonstrated with patients that
contain ATGL gene mutations. Similar to ATGL null mice, there is massive TAG
accumulation located in multiple tissues as well as the development of cardio myopathy,
which is highly lethal (Lass et al. 2011). ATGL mediated TAG catabolism is an essential
in all cells and when deficient, there is inability to maintain normal energy metabolism
during fasting or energy expenditure (Lass et al. 2011). However, in studies analyzing the
effect of high fat diet included obesity, there is disrupted signaling in the lipolytic
cascade inducing upregulation of ATGL and its co-activator CGI-58. This results in
increased basal lipolysis but blunted catecholamine-induced lipolysis yielding a
dysfunctional mechanism, increased circulating NEFA, and contributing to obesity
induced metabolic disease state (Gaidhu et al. 2010).

1.6.3

HSL

HSL was first discovered in the 1960s in which its isolation and characterization
in adipose tissue demonstrated its innate ability to hydrolyze both DAG and TAG
(Zechner et al. 2012). However, this 84 kDa cytoplasmic enzyme has a much greater
affinity for DAG with relatively an eleven fold higher hydrolase activity toward DAG
than TAG and preference for FA in the sn-1 or sn-3 position (Duncan et al. 2007;
Lafontan and Langin 2009; Raclot 1997). Much of the recent knowledge of HSL stems
from a study done with HSL-null mice, which demonstrated no changes in TAG
accumulation in adipose tissues and nonadipose tissue, yet the level of DAG was
enhanced (Haemmerle et al. 2002; Zechner et al. 2012). This led to the accepted thought
that HSL is the second rate-limiting step in lipolysis and ATGL is responsible for initial
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TAG hydrolysis. HSL also retains specificity to other lipid ester bonds such as
cholesteryl esters, retinyl esters, and short-chain carbonic acid esters (Duncan et al. 2007;
Zechner et al. 2012). The largest expression concentrations of HSL mRNA and protein
include white and brown adipose tissues, although there is some low levels seen in other
organs (Zechner et al. 2012). To date, there are three regions of HSL which make up its
functional capacities including the N-terminal domain, C-terminal domain, and a third
region presenting as the controlling component (Lafontan and Langin 2009). The Nterminal region has been suggested as the modulator of lipid binding, dimerization of the
enzyme, and interface with FA binding protein 4 (FABP4) (Lass et al. 2011). The action
of HSL is increased by the presence of aP2 and FABP4, both which interact and aid in
the movement to the surface of LD (Wang et al. 2008). The C-terminal domain contains a
  


            

      

    

 (Lass et al. 2011;

Yeaman 1990).
HSL is regulated by hormones, similar to ATGL, and thus results in the second
       -adrenergic stimulation, HSL is the target of PKA

phosphorylation and other kinases which regulate its enzymatic activity (Lass et al. 2011)
(Zechner et al. 2012). HSL phosphorylation at 5 serine residue sites by PKA, AMPK and
MAPK are a critical regulatory steps for hormone-induced lipolysis and increases HSL
lipolytic activity (Zimmermann et al. 2009) (Walther and Farese 2012). Through overall
modulation of cAMP levels, catecholamines and insulin levels play a role in the
regulation of HSL action (Lafontan and Langin 2009). This phosphorylation also allows
for the recruitment of HSL to the surface of the LD and increased HSL activity 100 fold
(Schweiger et al. 2006). The regulation of HSL induces a two-step process of activation:
PKA phosphorylates HSL at several serine sites (Ser81, Ser222, and Ser276) resulting in
translocation from the cytosol to the LD and binds HSL to a perilipin adipose
differentiation-related protein, and secondary phosphorylation of serine-660 (Ser660) is
responsible for the imperative LD interfacial activation and hydrolysis (Walther and
Farese 2012; Wang et al. 2009). The activation of the signaling kinase pathway which
stimulates lipolysis via phosphorylating HSL at Ser660 has been demonstrated in vitro
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(Greenberg et al. 2001). The lack of HSL greatly affects overall adipocyte function and
the hydrolysis of DAG and release of NEFA (Zimmermann et al. 2009).

1.6.4

MGL

The final step in lipolysis is catalyzed by MGL, the rate-limiting point for
   

              

resultant after the intracellular TAG hydrolysis by ATGL and DAG by HSL, and occurs
in the cytoplasm of the cell (Zechner et al. 2012). This 33 kDa lipase was found in 1975
and purified from rat adipose tissue with its role clarified as the monoacylglyeride
enzyme (Tornqvist and Belfrage 1976). MGL is responsible for cleaving the 1(3)- or 2ester bonds of MAG, with specificity to only MAG, and no observed activity against
TAG, DAG, or cholesteryl esters (Duncan et al. 2007). Similar to the other lipolytic
     

       

  ld

(Karlsson et al. 1997) ! " "           ! #$$
in a GXSXG motif, Ap239, and HIS 269; mutation at any of these sites results in
complete ablation of its lipase ad esterase activity (Duncan et al. 2007; Lafontan and
Langin 2009; Lass et al. 2011). MGL is highly expressed in adipose tissue, but has been
seen in other tissues (such as kidney and testis), and has demonstrated its ability to
degrade MAG has been studied intensively via mutant mouse models (Chanda et al. 2010;
Lass et al. 2011; Zechner et al. 2012). Without MGL activity in adipose tissue the
lipolysis process is compromised and increases in levels of MAG are observed (Zechner
et al. 2012). Recently, a new role for MGL in endocannabinoid signaling has been
suggested, yet more investigations to fully understand its role in regulating appetite, pain
sensations, and mood control need to be addressed (Lass et al. 2011). Currently, the
literature reveals that the activity of MGL is not dependent upon hormonal stimulation,
but necessary for complete degradation of TAG in vitro (Zimmermann et al. 2009). MGL
activity has not been observed as rate limiting due to the abundance of the enzyme.
Nonetheless, it plays a pivotal role as a modulator of 2-acylglyerol level release of the
final NEFA, and is the last, but necessary step for the lipolysis process (Chanda et al.
2010; Zimmermann et al. 2009).
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1.6.5

Perilipin

Perilipins are proteins which are tightly associated with adipocyte LD at the
surface (Clifford et al. 1998). There are three protein isoforms stemming from the
translation of alternatively spliced mRNA. These include perilipin A, which the largest
with 517 amino acids (AA) and found in high numbers on the surface of the LD in
adipocytes; perilipin B, that shares 405 AA with perilipin A , and perilipin C (Brasaemle
2007). Perilipin C is the shortest isoform of the three and is expressed solely in
steroidogenic tissue cells (Brasaemle 2007).
For lipolysis to occur, soluble lipases need to access a hydrophobic LD and begin
action on the TAG substrate, and perilipin proteins are a prerequisite for their action and
contact with the LD (Duncan et al. 2007). During lipolysis perilipins are highly
phosphorylated and stimulated by PKA, alongside HSL. Perilipins which lack
phosphorylation by PKA, act as a barrier to lipid lipases and protect against hydrolysis
(Clifford et al. 1998). The primary LD associated protein that is present in mature
adipocytes is perilipin A(1), both in differentiated 3T3-L1 cells and murine primary cells
(Brasaemle et al. 2000) (Shen et al. 2009). Perilipin A is a member of the PAT family and
regulates WAT breakdown by controlling ATGL and HSL via mediating activity (Lass et
al. 2011). It is highly expressed in adipocytes and interacts with the LD, specifically at
the three C-terminal hydrophobic stretch (these are able to penetrate the LD) (Walther
and Farese 2012). At the surface of the LD, perilipin A contains an amphipathic area,
which has been suggested to add to lipid binding (Walther and Farese 2012). In
unstimulated conditions, ATGL and HSL are located at the surface of the LD and are
seen up to 50%; perilipin A and B which coat the LD are the only functional barrier that
inhibit their action (Brasaemle et al. 2000). Perilipin A, the greatest phosphorylated
protein behind PKA, plays an imperative role in the modulation of both basal and
stimulated lipolysis. This is demonstrated by increased basal lipolysis and perilipin null
mice loss of PKA-stimulated lipolysis (Martinez-Botas et al. 2000; Shen et al. 2009).
Simultaneous to HSL phosphorylation, PKA also phosphorylates perilipin A on six
different serine residues (Shen et al. 2009; Wang et al. 2009; Zechner et al. 2012).
Increased TAG storage and inhibition of lipolysis has been observed with increased
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expression of perilipin A. Discovered in 3T3-L1 cells, preadipocytes subjected to
perilipin A transfection showed large reductions in lipolytic rates and even larger
increases in TAG storage (Brasaemle et al. 2000; Duncan et al. 2007). Perilipin proteins
located on the LD are critical for PKA stimulation of HSL translocation, and has been
shown to be necessary for maximal lipolysis (Miyoshi et al. 2006). The phosphorylation
of perilipin by PKA may also enable interaction with HSL on the LD, thus increasing
enzymatic activity (Duncan et al. 2007; Miyoshi et al. 2006). Perilipin, during fasting
conditions, also allows for the recruitment of ATGL and CGI-58 to the LD via
dissociation of CGI-58 from perilipin A and activation of ATGL (Ho et al. 2011) (Lass et
al. 2011; Zechner et al. 2012). Although these proteins are not critical for LD
establishment, they are necessary in regulating lipid metabolism (Walther and Farese
2012). Overall perilipin A plays an important dual role in regulating lipolysis, first in
preventing basal lipolysis and second upon PKA stimulation, increasing the process
(Langin 2006a; Shen et al. 2009).

1.7

NEFA

Under normal conditions, NEFA have the ability to act as a fuel source alternative
to glucose, occurring most often during times of fasting or increased energy expenditure
(Unger 1995). In a fed state, insulin acts as an antilipolytic agent by suppressing NEFA
levels and allowing glucose to be metabolized (Unger 1995). In obesity and type 2
diabetes, plasma NEFA are elevated in these conditions due to their lack of suppression
by feeding as a result of insensitivity to insulin by adipocytes or increase in adipocyte
mass (Kahn et al. 2006; Unger 1995). Excess NEFA toxicity, along with reduced normal
oxidative metabolism frequently results in ectopic fat accumulation in non-adipose
 



 



-cell dysfunction, cardiomyopathy and hepatic steatosis;

termed lipotoxicity (Weinberg 2006). Excess lipid accumulation in other tissues other
than adipose tissue can result in severe metabolic complications, including insulin
resistance, diabetes, coronary heart disease, and even heart failure (Listenberger et al.
2003). Evidence has shown that increased circulating NEFA are contributors to this
deposition to non-adipose tissues causing lipotoxicity and subsequent disorders
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(Listenberger et al. 2003) as shown in Figure 1.3. Multiple pathways can be altered as a
result of both acute and chronic effects of excess NEFA concentrations (Weinberg 2006).
NEFA are imp        

-cell function and adaptive response to

       -cell dysfunction leads to weakened glucose tolerance and fasting
glucose, and can lead to insulin resistance and type 2 diabetes (Kahn et al. 2006). The


 -cell function is progressed by increased NEFA plasma levels, with chronic

exposure of NEFA resulting in impaired glucose stimulated insulin secretion, insulin
biogenesis and induction of apoptotic     

-cells (Sarafidis and

Bakris 2007). Thus, NEFA at amplified levels are a primary factor mediating the link
   

      

 



       



 -cell

dysfunction (Kahn et al. 2006).
NEFA plasma concentrations are increased in an obesogenic condition and are
highly indicative of the dysregulation of lipolysis (Lafontan and Langin 2009). Two
components of lipolysis which could contribute to obesity include reduced plasma
delivery from adipose tissue during energy expenditure or fasting, or impaired
suppression of NEFA by insulin. The latter leads to the therapeutic potential of
identifying antilipolytic agents due to the fact excessive lipolysis results in high
circulating levels of NEFA and development of dyslipidemia and metabolic syndrome
(Langin 2006a). Insulin mediated glucose uptake in cells as well glucose tolerance has
been shown to improve upon acute action with an antilipolytic agents which helps to
reduce NEFA levels (Kahn et al. 2006). It has been shown that cellular TAG
accumulation is not toxic and in fact, accumulation in TAG pools of surplus NEFA,
rather than locating to other pathways (in non-adipose tissues) that lead to cytotoxicity,
act as a buffer against lipotoxicity (Listenberger et al. 2003). Thus, identifying
antilipolytic agents which prevent lipolysis can be used as a therapeutic approach to
avoid amplified NEFA levels all together.

1.8

Lipolysis as a therapeutic target for metabolic disease

With obesity, a state of sufficient increase in adipose tissue mass causing adverse
health effects, dramatically increased, so has the amount metabolic disorders (Spiegelman
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and Flier 2001). Metabolic syndrome is described as an array of contributing factors
which negatively impact human health which includes insulin resistance, visceral (central)
obesity, hypertension, a proinflammatory state, and increased circulating TAG and NEFA
concentrations (Gertow et al. 2006). Obesity is associated with many metabolic
syndromes, but specifically obesity results in an increase in basal levels of lipolysis,
which can lead to insulin resistance (Duncan et al. 2007). Although basal lipolysis can be
cut in half upon weight loss, often the desire to lose is greater than action taken (Brown
2013; Reynisdottir et al. 1995). Insulin insensitivity in adipocytes is a contributing factor
 



 

  

 

-adrenergic receptors to stimulated lipolysis are

often compromised in an obese individual (Duncan et al. 2007). Increased levels of
lipolysis results in enhanced levels of circulating NEFA which are highly correlated to
harmful whole body metabolic effects as discussed above.
There is therapeutic potential in regulating and manipulating lipolysis as a means
to reduce levels of NEFA. In an obesogenic condition, multiple disorders can arise as a
result of adipocyte lipolysis including ketogenesis, ketolysis, mitochondrial disease, and
glycogen storage diseases (Wang et al. 2008). It was observed that both obese and nonobese relatives of obese patients alike share in atypical lipolytic processes (Wang et al.
2008). Lipolysis suppression could be very beneficial with inborn errors of fatty acid
oxidation (FAO) and ketone metabolism (Wang et al. 2008). Altering lipolysis has large
potential in re-balancing NEFA flux and regulating fat mass as a way to reduce the risk of
obesity-induced complications in metabolic syndrome.
Currently, identification of mechanisms and potential targets to develop antiobesity drugs are being done, many which relate to metabolic syndrome (Grundy 2006).
Specifically in adipose tissue, there are metabolic pathways which could be significant in
targeting as obesity contributors to metabolic syndrome conditions. However, drug
development is in preliminary stages and remains to be safe and effective, especially if
chronic use is needed with minimal side effects (Grundy 2006). Specifically, identifying
compounds which inhibit lipolysis in an effort to lower serum levels of NEFA is a
strategy to manage obesity associated diseases, like type 2 diabetes (Ahmadian et al.
2010). Increased NEFA being released at higher rates than oxidative capacity can also
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cause ectopic TAG storage and lipodystrophy; and chronic levels of NEFA in circulating
plasma can have a lipotoxic effects (Ahmadian et al. 2010; Lass et al. 2006). Taken
together a vicious cycle ensues with increased mobilization of NEFA from adipose tissue,
typically suppressed by insulin, yet adipocytes that become insulin resistant,
consequently lipolysis is further increased (Karpe et al. 2011). Therefore identifying was
to alleviate lipolysis and NEFA release will in turn produce approaches to treat obesityinduced metabolic syndromes.

1.8.1

Lipolysis and cancer cachexia

Lipolysis may also be involved in cancer-associated cachexia (Zechner et al.
2012). Cancer cachexia is defined as an intricate metabolic syndrome commonly
associated with illness and characterized by persistent erosion of body mass due to a
malignant growth. It has also been termed as an auto-cannibalism or wasting disease
(Evans et al. 2008). Also commonly associated with cancer cachexia is anorexia,
inflammation, insulin resistance, anemia, and hypogonadism (Evans et al. 2008). This
wasting disease is primary due to the involuntary loss of skeletal muscle and adipose
tissue, which are the majority and best studied targets of cachexia (Beutler and Cerami
1988). Typically, there are increased circulating factors that can induce lipolysis which
include TNF- -6 and zinc--glycoprotein 1 (Zechner et al. 2012). TNF-   
as a mediator of cachexia via its stimulation of adipocyte breakdown (Tracey et al. 1988).
Cancer patients with cachexia have been observed to have higher activity of lipolytic
enzymes, NEFA and glycerol levels, suggesting that lipolysis signaling is involved in the
severe loss of adipose tissue and muscle. Although the fundamental mechanisms remain
unknown, inhibition of lipolysis may play a role in helping to prevent or attenuate
cachexia in people with cancer or other diseases (Evans et al. 2008; Zechner et al. 2012).

1.9

Dietary intervention of obesity

As the obesity epidemic continues to progress, there is large opportunity for
functional ingredients that may be beneficial for weight control to be used in food
product development (Kovacs and Mela 2006). Therefore, to establish a dietary
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intervention strategy to combat obesity, a variety of factors need to be taken into
consideration for practical feasibility. In addition, to mechanistic and clinical efficacy
evidence, a proposed food ingredient should satisfy other criteria including safety,
stability in processing and shelf life, raw ingredient quality and reliable sourcing,
regulatory usage levels and dosing schedule, cost, and adequate and appealing food
vehicle (Kovacs and Mela 2006). Bioactive components from food are attractive due to
their extensive history of safe consumption as well as their health benefits, including
weight control. The following focuses on dietary sources of functional components that
help to prevent weight gain, aid in weight control, or reduce risk factors associated with
excessive adipose mass.

1.9.1

Role of phytochemicals in adipose function

The potential for natural products to combat obesity is large due to the
dissatisfaction of current anti-obesity drugs on the market (Yun 2010). Natural products
that could be used to treat obesity include crude extracts or plant sourced isolated
compounds. There have been many studies identifying and demonstrating the benefit of
different dietary components in regards to their impact on energy balance (Astrup et al.
2010). Specifically, research has aimed to improve our understanding how bioactive food
component help to inhibit energy storage, reduce lipid uptake or formation, stimulate fat
mobilization, or increase levels of fat oxidation via different mechanisms (Kovacs and
Mela 2006).
Adipocytes play a large role in overall homeostasis and energy balance by storing
TAG and releasing NEFA based on energy demand as previously described. Studies have
looked to identify anti-obesity biomaterials which inhibit adipocyte proliferation or
differentiation (Yun 2010). However, contemporary research have suggested that
inhibiting adipogenesis can be unhealthy and may lead to pathogenesis of type 2 diabetes
or other metabolic diseases (Lefterova and Lazar 2009). Therefore pharmacological
targeting of lipolysis has been investigated to help partially block the release of the
already high levels of circulating NEFA in obesity and dyslipidemia. Many of the natural
components which had been found to affect lipolysis do so by stimulation or activation of
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the lipolytic pathway rather than reduce it. It was found that Nobiletin, a
polymethoxylated flavone found in citrus fruits, dose-dependently stimulated lipolysis in
3T3-L1 adipocytes through activation of cAMP/PKA pathway (Saito et al. 2007). Toona
sinesis leaf extracts have also been shown to enhance lipolysis in differentiated 3T3-L1
cells (Hsu et al. 2003). The aromatic compound of red raspberries, raspberry ketone, has
the ability to increase norepinephrine induced lipolysis in white adipocytes through
enhanced translocation of HSL to the surface of the LD (Morimoto et al. 2005). The hot
water soluble extract of Salacia reticulata, which is a Hippocrateaceae plant,
demonstrated stimulation of lipolysis in rat epididylmal adipocytes (Yoshikawa et al.
2002). Oolong tea also has anti-obesity properties through its major bioactive component,
caffeine, that acts on the lipolysis process via interactions with LD lipases (Han et al.
1999; Yun 2010). In fact, caffeine and other methylxanthines stemming from tea and
coffee are well characterized and known to stimulate lipolysis through increases in cAMP
levels (Duncan et al. 2007). Flavonoids genistein, diadzein, coumestrol, and zeralenone
all show a dose-dependent effect in enhancing lipolysis in rat adipocytes, along with
quercetin, luteolin, and fisetin, imposing dose- and time-dependent increases (Rayalam et
al. 2008a). Resveratrol, a highly studied polyphenol found in grapes, has also been
studied in regards to its stimulatory effect on lipolysis through activation of ATGL (Lasa
et al. 2012b). Ethanol contains acute antilipolytic effects resulting in reduced levels of
FFA in serum as well as in chronic conditions adipocytes show s 

-

adrenergic receptor mediated lipolysis (Duncan et al. 2007; Kang et al. 2007). Of these
dietary sources, most show an induction of lipolysis, and few food components have
demonstrated an antilipolytic effect.

1.10 Resveratrol and resveratrol metabolites
Resveratrol (trans-

-trihydroxystilbene) is a phytoalexin polyphenolic,

naturally occurring compound that is produced in plants when there is a pathogenic attack
or induced stress, not exclusive to fluctuations in climate, sunlight, and heavy metals
(Athar et al. 2007; Fremont 2000). It is present in food such as berries, grapes, and
peanuts and has many biological activities which include acting as an antioxidant, anti-
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inflammatory, neuroprotective, anti-aging, anti-cancer, and cardioprotective (Baur and
Sinclair 2006; Fremont 2000; Wang et al. 2004). The efficacy of oral administration of
resveratrol depends on absorption, metabolism, and tissue distribution, yet rapid
metabolism generally leads to the production of sulfates and glucuronides (Baur and
Sinclair 2006; Hoshino et al. 2010). Due to the nature of the breakdown, it has been
suggested that the physiological significance of having increased concentrations of
resveratrol, used in in vivo studies, more likely should be given to resveratrol metabolites
and their effects (Hoshino et al. 2010), structurally shown in Figure 1.4. Levels of
resveratrol are generally exceeded by resveratrol metabolites due to phase II metabolism
and longer plasma half-life of its metabolites; resveratrol has a short plasma half-life
while the metabolites can maintain a plasma half-life of 9.2 hours (Athar et al. 2007;
Patel et al. 2010). Due to its rapid breakdown and extensive metabolism, there is a 20
fold higher concentration of resveratrol conjugates which circulate, than resveratrol itself,
equating to less than 1% (Andres-Lacueva et al. 2012). This is a major issue in

          functional compound, and raises the
question of the biological activities and the effect of resveratrol metabolites themselves
(Lasa et al. 2012a).
Research that has investigated resveratrol and its metabolites in vivo has detected
glucuronide and sulfate conjugates, with only a small amount of resveratrol that was left
unaltered (Hoshino et al. 2010; Urpi-Sarda et al. 2005). For example, it was shown that
with oral ingestion of 25 mg of dietary relevant resveratrol, plasma concentration
detected was in the nanomolar range, whilst its metabolites maintained levels in the
micromolar range (Calamini et al. 2010; Walle et al. 2004). It has also been reported that
generally speaking, glucuronides have been the leading metabolite in rodents, whereas
sulfates are more prevalent in human plasma (Burkon and Somoza 2008; Emilia Juan et
al. 2010; Lasa et al. 2012a). After glucuronidation and sulfation of resveratrol in both the
gut and liver, resveratrol metabolites are taken up dependently by ABC transporters
(Kenealey et al. 2011). The distribution of the resveratrol metabolites also depends on
specific location, the concentration delivered, and the species (Andres-Lacueva et al.
2012). These facts suggest that if not most, some of the biological effects stimulated by
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resveratrol should be attributed to its metabolites (Hoshino et al. 2010) and their activity
(Wenzel and Somoza 2005). Furthermore, resveratrol metabolites have shown significant
effects in biological activities (Lasa et al. 2012a).
Research identifying tissue distribution of resveratrol metabolites has primarily
focused on profiling the liver, kidney, lungs, brain, and testis, however more recently,
resveratrol metabolites were found located at intermediate levels in adipose tissue and
even low levels in skeletal muscle (Andres-Lacueva et al. 2012). The majority
investigations of resveratrol metabolites are researched in regards to their distribution and
profile of their relative levels in tissues, with limited studies focusing their action.
Resveratrol metabolites do exhibit levels of antioxidant activity, yet it is lower than the
parent compound because their radical scavenging OH groups may be blocked by
sulphation, glucuronidation, or methylation (Halliwell 2007). In a study investigating the
chemoprotective activity of sulfate metabolites of resveratrol, two were able to inhibit
COX activity and NO production (Hoshino et al. 2010). It has also been demonstrated
that resveratrol metabolite, resveratrol--O-sulfate inhibits COX-1 and COX-2 activity,
which help to exert cardioprotective and anticancer effects. Other sulfate metabolites,
have been suggested to promote longevity through inhibition of SIRT1 (Calamini et al.
2010). Resveratrol-3-O-sulfate was able to inhibit colon cancer cell proliferation having
the potential to act as a chemotherapeutic drug to induce apoptosis (Aires et al. 2013).
Interestingly, a mixture of metabolites, resveratrol-3-O-sulfate, resveratrol-3-O-Dglucuronide and resveratrol--O-D-glucuronide, induced anti-proliferative activity
greater than resveratrol (Aires et al. 2013). It has also been reported that the sulfate
conjugates have anti-inflammation properties (Hoshino et al. 2010; Lasa et al. 2012a).
Piceatannol (3, 3  -trans-trihydroxy stilbene) another resveratrol metabolite, has also
shown potential to have activity in activation of AMPK and GLUT4 translocation,
suggesting prevention and improvement for diseases such as type 2 diabetes (Minakawa
et al. 2012). Also it has been studied for its antioxidant, anti-cancer, and apoptotic effects
(Piotrowska et al. 2012). Accordingly, resveratrol metabolites are involved in diverse
biochemical processes that have the potential to exert positive health promoting effects;
yet their action is dependent on the specific function investigated.
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1.10.1 Resveratrol metabolites in lipid metabolism
Currently, there is minimal knowledge of the effect of resveratrol metabolites in
adipose tissue and lipid metabolism. One study demonstrated several resveratrol
metabolites had a significant reduction of TAG levels in maturing pre-adipocytes and
mature adipocytes (Lasa et al. 2012a). Resveratrol- -O-glucuronide and resveratrol 3-Osulfate both showed significant reductions in lipid species in maturing pre-adipocytes
greater than resveratrol. Resveratrol-3-O-glucuronide and resveratrol- -O-glucuronide
both showed delipidating effects in mature adipocytes. Taken together, resveratrol
metabolites, target both maturing pre-adipocytes as well as mature adipocytes and may
been involved in anti-obesity effects (Lasa et al. 2012a)
In studies identifying the tissue distribution and levels of resveratrol metabolites,
have noted that not all the metabolites have been identified (Cottart et al. 2010). There is
large inter-individual variability in metabolism and the fate of up to 30% of resveratrol
dosage may not be recovered in urine or feces. Due to the various distribution of
resveratrol and its metabolites, there may be other metabolites which have been bound to
cellular membranes of lipophilic fractions and tissue and gone undetected (Cottart et al.
2010). Therefore other resveratrol metabolites, such as trans-  -trimethoxy
resveratrol could also have potential and bioactive functionality. Identification of
 

   

 

 

          



bioavailability and rapid metabolism, and be a an alternative source for increasing health
(Minakawa et al. 2012).
1.11 Trans-  -trimethoxy resveratrol
Stilbenes are widely available in foods such as mulberries, grapes, red wine, and
peanuts (Shi et al. 2012). Food and herbs which contain beneficial phytochemicals have
potential at curbing the increase of metabolic disorders and diseases. Although studies
have supported the use of resveratrol in prevention of diseases, stilbenes related to
resveratrol with the same backbone but differing substituents may contain greater
potency (Dias et al. 2013). In an attempt to understand the role of resveratrol analogs that
possess biological effects, new attention has been turned to trans-  -
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trimethoxystilbene or trans-   -trimethoxy resveratrol (TMR). It is naturally found in
the Pterobolium hexapetallum plant (Aggarwal et al. 2004) and has also be isolated from
Virola cuspidata (Blair et al. 1969). The methoxy groups attached to TMR enhances the
transportation to cells as well as metabolic stability; it is partially protected from further
metabolism by enzymatic glucuronidation or sulfation. Also, TMR has greater
lipophilicity and is highly likely to be distributed into fat tissues, and generally found in
larger amounts in major organs than plasma (Dias et al. 2013). In a pharmacokinetic
study, TMR maintains enhanced properties in clearance, plasma exposure, as well as
absolute bioavailability (Lin et al. 2009).

1.11.1 Anti-cancer activity
Dietary factors that have the ability to modify progression and carcinogenesis are
of large interest in epidemiological studies. Several studies have identified TMR as a
potential anti-cancer agent, acting in vitro and in vivo, for its chemoprotective properties
in various cancer types which include colon, leukemia, breast, and prostate. TMR has
been shown to be different that other stilbenes in regards to its mechanism of cytotoxicity
on neoplastic cells; suggesting its efficacy in different cancers (Simoni et al. 2006). TMR
observed in HL60 cells, was highly active due to its structure-function activity
relationship. The methoxy derivatives from resveratrol showed significantly better
activity against HL60 leukemic cells (Simoni et al. 2006). Also noted, was that in many
studies, stilbenes act as phase-specific drugs, blocking cells in a specific phases of the
cell cycle. For example, resveratrol and piceatannol induced a block in the S phase,
suggesting that they act as phase-specific cytotoxic agents. However, TMR demonstrated
no modification in cell cycle distribution (G0-G1, S, or G2-M) compared to the control.
Overall, TMR maintained cytotoxic and apoptotic-induced activity and an ability to
reduce neoplastic cells in all phases of the cell cycle (Simoni et al. 2006). TMR also was
more potent than resveratrol against different human cancer cells lines including HT-29
(human colon adenocarcinoma), PC-3 (human prostate cancer), and COLO25 (human
colorectal carcinoma) (Pan et al. 2008). The presence and location of the methoxy groups
can be attributed for the biological activity, seen within hours of treatment. The induction
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of apoptosis with TMR treatment is credited to its strong inhibition of cell viability,
causing potent apoptosis and DNA laddering in COLO25 cells (Pan et al. 2008). TMR is
thought to trigger apoptosis via p53 dependent proteins and effecting mitochondrial
function. In vivo, TMR significantly reduced tumor growth in SCID mice with no
cytotoxic effects in the mice when dosed at 50 mg/kg (Pan et al. 2008). Taken together,
TMR may have potential in inhibiting cancer proliferation in colorectal carcinomas.
Similarly, in human prostate cells, TMR showed limited DNA damage, which
could trigger reduced stimulation of p53 and subsequently p21 (Hsieh et al. 2011a). TMR
maintained little effect on the cell cycle transition in CWR22Rv1 cells, but did decrease
G1 and expanded G2M in PC-3 cells, different from other resveratrol metabolites. This
suggests that TMR is active against different stages in prostate cancer cells and may use
distinct mechanisms (Hsieh et al. 2011a). TMR studies in cell proliferation assays in
three types of cells, LNcaP, Du145, and PC3M, demonstrated higher potency in growth
inhibition than resveratrol with highest potency in LNCaP cells (Dias et al. 2013). Also,
TMR dose-dependently inhibited colony formation in LNCaP-Luc cells in vivo with large
reductions in size and number of colonies (Dias et al. 2013). Finally, to elucidate the anticancer effects in vivo using xenografts with prostate cancer cells, TMR pretreatment in
mice helped to attenuate tumor development and progression. It was proposed that the
phytochemicals created a microenvironment in which tumor initiation and development
was reduced. Reported data shows TMR had enhanced anti-proliferative, anti-clonogenic,
and anti-inflammatory properties, also higher amounts of TMR located in serum and
target tumor tissue compared with resveratrol (Dias et al. 2013). With in vitro studies
with breast cancer cell lines, TMR was able to induce apoptosis. And in biochemical
analysis it is suggested that upon      

   

pathway is stimulated leading to p53 activation and apoptosis which is different than
routes seen with resveratrol and piceatannol (Hsieh et al. 2011b).

1.11.2 Antiangiogenic activity
Uncontrolled endothelial cell proliferation is commonly seen in tumor
neovascularization and angioproliferative diseases. Two models to affect
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neovascularization include identification of antiangiogenic compounds which prevent
new blood vessel development, and disruption by vascular-targeting agents within
neovasculature (Belleri et al. 2005). TMR has demonstrated efficacy in both areas and is
identified as a microtubule-destabilizing agent, causing rapid, microtubule
depolymerization in endothelial cells. Results indicated that TMR has antiangiogenic and
vascular-targeting capacity and inhibits tumor proliferation (Belleri et al. 2005).
TMR evaluated for its cytotoxicity in human cancer lines was studied in human
endothelial cells and zebra fish blood-vessel formation in vivo (Alex et al. 2010). TMR
demonstrated its high potency as an antiangiogenic and vascular disrupting agent, greater
than resveratrol in vitro and in vivo. TMR showed different efficacy in three cancer cells
lines (HepG2 (human hepatoma), and human breast adenocarcinoma (MCF-7 and MDAMB-231)) in vitro, compared to resveratrol. And in HUVECs (human umbilical vein
endothelial cells) in vitro and zebra fish embryo in vivo,

  

   

was more potent and expressed greater specific cytotoxic effects on endothelial cells.
Mechanistically, further insight showed TMR may act through down regulation VEGFR2
expression in the VEGF/VEGR pathway and cause cell-arrest at G2/M phase (Alex et al.
2010).

1.11.3 Other bioactive properties

                         
system which induces a defense system to harmless substances (Matsuda et al. 2004).

             -hexosaminidase by ionomycin in
RBL-2H3 cells, which correlates to anti-allergenic activity (Matsuda et al. 2004). In
murine hippocampal HT22 cells, TMR failed to protect the cells from glutamine-induced
cytotoxicity and was unable to increase HO-1 expression and SIRT1 activation. HO-1 has
been reported as one of the main mediator of antioxidant activity and cytoprotection
(Kim et al. 2012). Therefore increased expression HO-1 is partially responsible for
cytoprotective actions in HT22 cells. The data suggests that the methoxy groups of TMR
interfere with its ability to resist oxidative stress (Kim et al. 2012).
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Overall, TMR presents as a biologically active resveratrol metabolite and analog
in variety of cellular functions and in different cells types. However, its specific role in
 

  





 

      









systems

reveals its activity and suggests it may have potential in a wide range of areas for
beneficial health effects.

1.12 In vitro model
In vitro systems used to study adipocyte function have been used for the last 30
years and helped to identify molecular mechanisms and distinct cellular events (Gregoire
et al. 1998). Cell lines which are morphologically similar to primary preadipocytes in a
fibroblast like shape, and are able to transform into round, lipid accumulating mature fat
cells have been established. Preadipose cell lines have already committed to adipocyte
lineage and are able to represent different stages of adipocyte differentiation (Cornelius et
al. 1994; Gregoire et al. 1998). One of most frequently used and studied cell lines
includes 3T3-L1 cells. They are beneficial in studying molecular events in adipocyte
biology because they are well characterized, a reliable model, and can be passaged
indefinitely allowing for a consistent source for investigation (Ntambi and Kim 2000).
Additionally, since these cells are derived from cloning their homogeneity helps to yield
conclusive results to different treatments. 3T3-L1 cells were initially selected as a
consistent model for preadipocyte differentiation because of their ability to accumulate
TAG (Cornelius et al. 1994). When injected into mice, 3T3-L1 preadipocytes not only
differentiated and formed fat pads, they were histologically indistinguishable from the
normal adipose tissue (Cornelius et al. 1994; Ntambi and Kim 2000). In cell culture
protocols, 3T3-L1 rapidly and in sync can proliferate and differentiate with very similar
characteristics of adipocytes from animal tissue; formation of LD are also very similar to
those seen in vivo adipose mass (Ntambi and Kim 2000). These cells are also very
coordinated to the pathways of de novo FA and TAG biogenesis demonstrated through
expression of every enzyme involved (Macdougald and Lane 1995).
Nonetheless, there are some disadvantages to using cell lines in studying
adipocyte biology. Being that these cells are aneupolid, they may not always accurately
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resemble preadipocytes found in vivo along with the fact that they are out of the context
of a normal extracellular matrix (Ntambi and Kim 2000; Rosen et al. 2000). And while
these types of cell lines have similar characteristics, across the board there may be
differences between the established lines. Presumably, these differences are due to the
stage of preadipocyte differentiation that the cloning occurred (Macdougald and Lane
1995). Preadipocytes in these cell lines represent early, intermediate, or late stage
development, therefore the response to different hormones or treatments may be varied
(Macdougald and Lane 1995; Ntambi and Kim 2000). Most all cell lines differentiate into
WAT exclusively, and do not represent any changes to BAT. Finally, preadipose cells
lines may not be derived from the same fat depot, which is an important consideration
because there are known differences in metabolic behavior of mature adipocytes between
visceral and subcutaneous fat pads (Rosen et al. 2000). However, almost all work in
investigating adipogenesis and other adipocyte functions have used clonal cells lines,
stemming from the stromal vascular fraction. Overall, established preadipose cells lines
used in vitro represent a useful tool in preliminary understanding of in vivo systems.

1.13 Conclusions and research objectives
Metabolic syndrome is associated with a variety of health risk factors including
abdominal obesity, blood lipid disorders, inflammation, insulin insensitivity, type 2
diabetes, and elevated risk of cardiovascular disease (Despres and Lemieux 2006). In an
obesogenic condition, dysfunctional adipose tissue is unable to appropriately store excess
energy and increased basal lipolysis occurs; leading to increased levels of circulating
NEFA which can have severe metabolic consequences (Duncan et al. 2007). A surplus of
NEFA results in uptake in non-adipose tissue and ectopic fat deposition which can induce
other conditions including dyslipidemia, hyperglycemia, inflammation, and insulin
resistance (Despres and Lemieux 2006). Studies identifying novel ways to alleviate
adipose lipolysis and NEFA release may provide approaches to treat obesity-induced type
2 diabetes and other metabolic syndromes. Identification of dietary components as a
strategy to combat obesity and its associated disorders may be via phytochemicals.
Currently, there is a knowledge gap in investigation the regulation of adipose tissue
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lipolysis by dietary components. To date, there is no clear evidence of adipose lipolysis
modulation by dietary components, expect one report recognizing resveratrol action on
the stimulation of lipolysis (Lasa et al. 2012b). Our lab has previously demonstrated that
piceatannol, a resveratrol metabolite, has antilipolytic activity in vitro and in vivo (Kwon,
unpublished). However, little is known about resveratrol metabolites, specifically, TMR,
in lipid metabolism and its affect in specific adipose functions. Thus, the work in this
thesis has been completed with the following objective, aims, and hypothesis.

Our overall working hypothesis is that resveratrol metabolites affect lipid metabolism by
modulating the lipolysis process.

Objective: Identify and determine the effect of different resveratrol metabolites and their
role in adipose function
Aim 1: Determine the effect of resveratrol metabolites on lipolysis in adipocytes in vitro
Aim 2: Determine the effect of resveratrol metabolites on lipogenesis in adipocytes in
vitro
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Figure 1.1 Cascade of 3T3-L1 preadipocyte differentiation and adipogenic program
in vitro. With the appropriate environment and gene expression induction, preadipocytes
undergo mitotic clonal expansion which is then followed by terminal differentiation. The
conversion is a result of up- and down-regulation of specific transcription factors and
genes. The process of differentiation takes place over the course of 6 days, beginning
with a fibroblast-like preadipocyte until full maturation of a round lipid-containing
adipocyte. Adapted from Gregoire and Ali (Ali et al. 2013; Gregoire et al. 1998).
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Figure 1.2 Lipolytic cascade in adipocytes. ATGL binds to CGI-58 and facilitates
lipolysis via hydrolysis of TAG to DAG and NEFA. With signal transduction from
    -adrenergic receptors ( -AR) and G protein-mediated signaling (Gs),
activates adenylyl cyclase(AC), resulting in increased levels of cAMP, activating PKA,
which phosphorylates HSL and perilipin A. Conformational changes occur in perilipin A,
and pHSL translocates to the surface of the LD and hydrolyzes DAG to MAG and NEFA.
Cytosolic MAG hydrolyzes MAG into NEFA and a glycerol backbone. NEFA and
glycerol are released into circulation. Adapted from Lafontan and Brasaemle (Brasaemle
2007; Lafontan and Langin 2009).
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Figure 1.3 Metabolic syndromes with ectopic fat distribution. Excess visceral fat
accumulation is associated with insulin resistance and also a marker of dysfunctional
adipose tissue due to inability for the body to appropriately store surplus energy. In
metabolic dysfunction, with high levels of circulating NEFA, fat deposition is stored in
undesirable locations including the liver, heart and muscle. Metabolic syndrome ensures
with this condition as well as other metabolic consequences including visceral obesity,
insulin resistance, dyslipidemia, and inflammation, which could result in increased risk of
other obesity associated disorders. Adapted from Despres (Despres and Lemieux 2006)
.
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Figure 1.4 Structure of resveratrol and resveratrol metabolites. (A) Resveratrol, (B)
Piceatannol, (C) Resveratrol- -O-glucuronide, (D) Resveratrol-3-O-glucuronide, (E)
Trans- -trimethoxy resveratrol.
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CHAPTER 2. MATERIALS AND METHODS

2.1

Introduction

To test our overall goal and achieve our specific aims we used a variety of
techniques to elucidate the effects of resveratrol metabolites. We utilized an in vitro
model by means of 3T3-L1 cells as an established cell line. The cells were passaged as
preadipocytes and differentiated into mature adipocytes and incubated in the presence of
different resveratrol metabolite treatments to understand their role in lipolysis. Upon
further investigation, preadipocyte cells were differentiated in the presence or absence of
trans-   -trimethoxyresveratrol (TMR) to gain understanding its role in lipogenesis.
We utilized both qualitative and quantitative techniques to investigate our findings.
Additionally, biochemical and molecular tools were used to gain knowledge into specific
mechanisms of action. The following accounts for the materials and methods used during
our research processes.

2.2

2.2.1

Materials and methods

Materials and reagents

Trans-   -trismethoxy resveratrol (TMR) was provided by Cayman Chemical
(Ann Arbor, MI). Trans-resveratrol-3-O--D-glucuronide (3G) and trans-resveratrol-O--D-glucuronide (4G) were obtained from Toronto Research Chemicals (North York,
ON, Canada). Piceatannol (PIC) was purchased from Alexis Biochemicals (Lausen,


                 

Thermo Scientific (Waltham, MA). Penicillin-streptomycin, sodium pyruvate, and 0.25%
trypsin EDTA were purchased from VWR (Randor, PA). Dexamethasone (DEX),
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3-isobutyl-1-methylxanthine (IBMX), insulin, free glycerol reagent and RNase Away
were purchased from Sigma-Aldrich (St. Louis, MO). Fetal calf serum (FCS) and fetal
bovine serum (FBS) were obtained from PAA (Darthmouth, MA). TRIzol® reagent as
well as SuperScriptII was bought from Invitrogen. Protein assay kit was from Bio-Rad
laboratories (Hercules, CA). 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Alfa Aesar (Ward Hill, MA). Antibodies against

 -actin, and secondary mouse antibodies were from Santa Cruz Biotechnology
(Santa Cruz, MA). Phospho-HSL (ser660) and secondary rabbit antibodies were obtained
from Cell Signaling Biotechnology (Beverly, MA). CGI-58 was used from BioVision
(Milpitas, CA). Acetonitrile, methanol, water (Mallinckrodt-Baker, Phillipsburg NJ), and
formic acid (Sigma-Aldrich St. Louis, MO) used in sample preparation and analysis were
certified HPLC-MS and ACS grade.

2.2.2

3T3-L1 cell culture

3T3-L1 preadipocytes were sourced from American Type Culture Collection and
were cultured in 10% (v/v) FCS-DMEM in a humidified environment with 5% CO2 at
37oC. Cells were designated known passages and were not cultured past passage nine.
Preadipocytes had new FCS-DMEM changes every two days until growth had reached
approximately 80% confluence, at which point cells were split and expanded into 100mm,
60mm, 6-, 12-, or 24-well plates for further proliferation until differentiation.
Preadipocytes were kept in a sub-confluent state until induced to differentiate after two
days of post-confluence (entitled Day 0), with standard adipogenic cocktail (DMI)
comprising of 1 µg/ml insulin, 5 µg/ml DEX, and 0.5 mM IBMX in 10% FBS-DMEM
for two days. After two days of incubation, 10% FBS-DMEM medium including only
insulin was added to the maturing adipocytes and at day four to solely 10% FBS-DMEM,
and was changed every two days until adipocytes are fully differentiated to mature cells
(day 8-10) when lipid droplets are clearly visible. Cells which had differentiated with
greater than 90% into mature adipocytes were used for experiments. All media consisted
of 100 U/ml penicillin, 100 µg/ml streptomycin and 0.11 g/L sodium pyruvate.
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2.2.3

Treatment condition

Purchased metabolites (TMR, 3G, 4G, and PIC) were each dissolved in dimethyl
sulfoxide (DMSO) as recommended by the supplier. Stock solutions were diluted to 50 or
100 mM and aliquots were generated to keep freeze-thaw cycles to a minimum, with a
maximum thaw number of three times. For treatment of cells, stock solutions were
diluted into DMEM media to a final working concentration and applied to cells.
Preadipocytes were induced to differentiate with the adipogenic cocktail and in the
presence or absence of a specific treatment and continued to receive treatment every two
days until day 6. Mature adipocytes at day 8 to day 10 after differentiation were treated
in serum free medium for a set period of time with the designated treatment conditional
to the experimental design.

2.2.4

Oil Red O (ORO) staining

ORO staining was done on day six to visualize and quantify intercellular lipid
droplet accumulation (Koopman et al. 2001). 3T3-L1 cells were subjected to oil red O
lipid soluble dye as described with protocol adjustments (Ramirezzacarias et al. 1992).
Briefly, medium was removed from cells in each well and washed twice with phosphate
buffered saline (PBS). Cells were then subjected to 3.7% formaldehyde for 0.5-1 hour at
room temperature or overnight at 4oC to fix the cells. Plates were then washed with
double distilled water twice and a filtered working solution of ORO was applied to fixed
cells and incubated at room temperature for greater than 30 minutes. Cells were then
rinsed with distilled water by submersion and dried. Scanned images were taken of OROstained cells. Quantification of ORO-stained lipid droplets was done with isopropyl
alcohol extraction and absorbance measured spectrophotometrically at 490 nm with a
microplate reader (Bio-Rad). The quantification was calculated based on the ORO stain
as a percent of the control.

2.2.5

Cell viability assay

A 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction
was utilized in order to determine the effect of different concentrations of trans-   -
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trismethoxy resveratrol (TMR) on cell viability. This assay allows for the quantification
of active mitochondrial function based on their ability to reduce the yellow MTT solution
in the presence of dehydrogenase enzymes into a purple formazan product (Gerlier and
Thomasset 1986). Both proliferating preadipocytes and mature adipocytes were incubated
with different concentrations of TMR for 24 hours in serum free DMEM. The cells were
then incubated with the MTT assay solution (0.5 mg/ml) for one hour at 37oC in 5% CO2.
Upon development of the violet precipitate, the contents were then dissolved in DMSO
and quantified by absorbance measured spectrophotometrically with a microplate reader
(Bio Rad) at a wavelength of 595 nm. The amount of formazan, calculated as a percent of
control, is representative of final cell viability.

2.2.6

Lipolysis assay

The measure of free glycerol in media samples is representative to the amount of
lipolysis that occurs in samples based on hydrolysis of triglycerides into free fatty acids
and a glycerol backbone. This method was used to determine the level of lipolysis in both
basal and stimulated conditions of fully differentiated cells. The free glycerol reagent
measures free glycerol by using the same coupled enzymes reactions and produces a
quinoneimine dye, observed as a purple hue. Serum free DMEM with 10 µM
isoproterenol and 0.5 mM IBMX (stimulated) or without (basal) added was added to
mature adipocytes in the presence or absence of the different resveratrol metabolite
treatments at different concentrations. After incubation periods, aliquots of the medium
were collected and analyzed for free glycerol. Samples of the media were gently mixed
with the free glycerol reagent and incubated at 37oC for 5 minutes according to supplier
protocol. Quantification of the product was measured spectrophotometrically at minimum
absorbance of 540 nm using a microplate reader (Bio Rad). The increase in absorbance is
directly proportional to the free glycerol concentration in the sample. Glycerol release
measurement was normalized by protein concentration.
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2.2.7

Immunoblot assay

Western blot analysis was employed to measure the amount of protein expressed
by cells treated with different experimental groups as described (Burnette 1981) with
modifications. The cells were cultured and treated as specified in each experiment and
collected by scrapping in phosphate buffer saline (PBS). Samples were immediately
centrifuged to remove excess PBS. Cell pellets were then transferred to lysis buffer
comprising of Tris-HCl (100mM (pH 8.0)), NaCl (100mM), 0.5% Triton X-100, protease
inhibitor blend, sodium fluoride (10mM) and sodium orthovanadate (1mM). The
concentration of protein was quantified with the Bradford method (Bio-Rad Laboratories,
Hercules, CA). 100 µg of protein sample were separated with a 10% sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) and transmitted to a nitrocellulose membrane. A
protein ladder, Precision Plus Protein Standards Kaleidoscope (Bio-Rad) was employed
to identify protein size (kDa). Membranes were blocked in 5% non-fat dry milk in 1%
Tween-Tris Buffered Saline (TTBS) for two hours at room temperature. Immunoblotting
was completed with respective primary antibodies at 4oC overnight, followed by washing
in 1% TTBS (3 times for 5 minutes). Signals were seen with horseradish peroxidaseconjugated secondary antibodies (Santa Cruz Biotechnology) which were incubated for
two hours at room temperature, followed by washing (3 times for 6 minutes) and
enhanced with Pierce enhanced chemiluminescence plus Western Blotting reagents with
autoradiography. Film was scanned and protein band intensity was quantified with NIH
 

 

          -actin.

Membranes were

stripped with a mild stripping buffer (0.2 M glycine, 0.1% SDS, 1% Tween20, pH 2.2 1 L
dd water) at room temperature, and re-blocked.

2.2.8

Total RNA isolation and real time reverse transcription polymerase chain reaction
(RT-PCR)
TRIzol® (Invitrogen, Carlsbad, CA) was used to extract total RNA from 3T3-L1

           

    ocyte

cells were treated for

duration of time depending on experimental design or during differentiation at various
concentrations of TMR. Media was aspirated and cells were washed with PBS. TRIzol ®
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was added to the cells, harvested, and stored at -80oC until subjected to RNA isolation.
The integrity of the isolated RNA was determined with NanoDrop 2000c
(ThermoScientific) using the 260nm/280nm ration. Samples that maintained a ratio
greater than 1.8 were used. 1µg/µl of isolated RNA was subjected to the reverse
transcriptase reaction utilizing SuperScriptII system, and cDNA was synthesized. Newly
synthesized cDNA was used for real time reverse transcription PCR reactions using
Applied Biosystems Step One real time PCR thermocycler. The cDNA was diluted and
amplified using a SYBR premixed Taq reaction mixture with PCR primers. Reactions
were performed in triplicate for each pair of 100 n/ml PCR primers with values


     -actin, expression. The forward and reverse primer

sequences used in the study are shown in Table 2.1. Analysis of RT-PCR data was


  T scheme and calculated as relative changes in gene expression.

47
Table 2.1. Primer sequences corresponding to genes used in quantitative RT-PCR
(F) represents nucleotide sequence for the forward primer and (R) represents nucleotide
sequence for the reverse primer.
Gene
PPA



(F) 5'- 3' sequence

(R) 5'- 3' sequence

CCC AAT GGT TGC TGA TTA CAA T

CTA CTT TGA TCG CAC TTT GGT ATT CT
TGT CAC ATC AGC CAC TTG AGT GT

FAS

GCC ACC CAC CGT CAG AAG

ACC

GAA TCT CCT GGT GAC AAT GCT TAT T GGT CTT GCT GAG TTG GGT TAG CT

SCD1

GGT GAT GTT CCA GAG GAG GTA CTA C AGC GTG GGC AGG ATG AAG

MGAT1

CTG GTT CTG TTT CCC GTT GT

TGG GTC AAG GCC ATC TTA AC

DGAT2

GCC GTG TGG CGC TAC TTC

GTG GTC AGC AGG TTG TGT GTC T

SREBP1c

GGC ACT GAA GCA AAG CTG AAT

GGC ACT GAA GCA AAG CTG AAT

Resistin

TGC CAG TGT GCA AGG ATA GAC T

CGC TCA CTT CCC CGA CAT

Leptin

CAC ACA CGC AGT CGG TAT CC

AGC CCA GGA ATG AAG TCC AA

Adiponectin GAT GCA GGT CTT CTT GGT CCT AA

GGC CCT TCA GCT CCT GTC A

Adipsin

GCT ATC CCA GAA TGC CTC GTT

TTC CAC TTC TTT GTC CTC GTA TTG

UCP1

GCC AAA GTC CGC CTT CAG AT

TGA TTT GCC TCT GAA TGC CC

PGC-

CCC AGG CAG TAG ATC CTC TTC AA

CCT TTC GTG CTC ATA GGC TTC ATA

Tfam

TCC TGA GGA AAA GCA GGC ATA T

CAT TTC ATT GTC GTA ACG AAT CCT A

NRF1

GCC GTC GGA GCA CTT ACT G

GGC CAT GAT TTC TGG AAG CA-

NRF2

TCC CAGGTT GCC CAC ATT

TGC CAA AAG CTG CAT ACA GTC T

MCAD

CAA CAC TCG AAA GCG GCT CA

ACTTGCGGGCAGTTGCTTG

CPT1

GCT GCT TCC CCT CAC AAG TTC C

GCT TTG GCT GCC TGT GTC AGT ATG C

Tbx1

GGC AGG CAG ACG AAT GTT C

TTG TCA TCT ACG GGC ACA AAG

Tmem26

ACC CTG TCA TCC CAC AGA G

TGT TTG GTG GAG TCC TAA GGT

Prdm16

CAG CAC GGT GAA GCC ATT C

GCG TGC ATC CGC TTG TG

ATGL

GAG ACC AAG TGG AAC ATC

GTA GAT GTG AGT GGC GTT

CGI-58

GGT TAA GTC TAG TGC AGC

AAG CTG TCT CAC CAC

HSL

TGT GGC ACA GAC CTC TAA AT

GGCATATCCGCTCTC

Perilipin

TGC TGG ATG GAG ACC TC

ACC GGC TCC ATG CTC CA

-actin

AGA TGA CCC AGA TCA TGT TTG AGA

CAC AGC CTG GAT GGC TAC GT
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2.2.9

Stimulated Raman scattering (SRS) and two-photon excitation fluorescence (TPEF)
imaging

Stimulated Raman scattering (SRS) imaging was performed on a femto-second
laser (InSight DeepSee, Spectra-Physics, Mountain View, CA) system, as described
previously (Wang et al. 2013; Zhang et al. 2011). Mature adipocytes were treated for
three hours with 50µM TMR and subjected to both SRS and TPEF imaging. Briefly, with
the stokes beam fixed at 1040 nm, the pump beam is tuned to 800 nm to match the CH2
stretch vibration at 2850 cm-1. A water immersion objective lens (60X, UPlanSApo,
Olympus, Tokyo, Japan) with numerical aperture of 1.2 was used to focus the light on the
sample. The average power used is 30 mW for the pump beam and 75 mW for the stokes
beam. For Two-Photon Excited Fluorescence (TPEF) imaging of intracellular TMR
compound, the pump beam at 800 nm was used as the excitation source. Forward signal
was detected by a PMT (H7422-40, Hamamatsu) after a 410/40 nm bandpass filter. The
imaging acquisition time is 10 µs per pixel. Images were analyzed using Image J software.

2.2.10 High performance liquid chromatography (HPLC) with ultraviolet (UV) detection
In order to determine the effect of TMR stability in media an HPLC system with
UV-VIS detector was used as previously described (Lin and Ho 2009; Lin et al. 2010)
with modifications. Briefly, TMR at 50 µM added to serum free medium incubated at
37C were collected at 0, 3, 6, 9 and 24 hours and stored at -80 C. Samples with 2%
formic acid in acetonitrile were vortexed and centrifuged at 14,000 x g for 5 minutes to
precipitate any proteins in the sample. Finally the supernatants were filtered through a
  

            !"  #

equipped and a Waters 2996 Photodiode Array Detector. Separation was achieved with a
RPC18column (XBridge BEH Shield RP18 2.5 µm, 2.1 x 100mm) through delivery of a
mobile phase of 95% acetonitrile-water (75:25, v/v) containing 5% and 0.1% formic acid
respectively at a flow rate of 0.25 ml/min with a run time of 10 minutes. TMR was
detected at a wavelength of 300 nm and quantified using calibration curves constructed
from serially diluted stock solutions of TMR prepared in the range of 500, 250, 75, and
 !
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2.2.11 Statistical analysis
Data are displayed as means ± SEM. Statistical analysis was performed using
SAS 9.3 software. One-way analysis of variance was used to determine significance of
treatment interactions and effect. Statistical significant comparisons between each group

    

           

performed in duplicate or triplicate, with representative images. P values lower than 0.05
were regarded as statistically significant.
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CHAPTER 3. RESULTS AND DISCUSSION

3.1

Introduction

The prevalence and growth of obesity has drastically increased and expanded into a
global health issue (Kim et al. 2013). Currently two thirds of the population in the United
States are overweight, with a third being considered obese (Ogden et al. 2014).
Consequently, obesity is highly associated with other metabolic diseases including
insulin resistance and type 2 diabetes, cardiovascular diseases, and certain cancers
(Despres and Lemieux 2006). Adipose tissue plays a critical role in whole body energy
homeostasis and lipid metabolism. Adipocyte development is a result of hypertrophy, an
increase in cell size, as well as hyperplasia, an increase in cell number (Kim et al. 2013).
Hypertrophy occurs in mature adipocytes and this process is critical for lipid storage and
secretion of hormones which maintain overall energy balance. Hyperplasia is responsible
for generation of new adipocytes primarily seen in adolescence and adult adipocyte
turnover (Kim et al. 2013). Both processes are targets for the prevention and or treatment
of obesity in therapeutic strategies.
Obesity is associated with metabolic diseases that include type 2 diabetes.
Currently, NEFA at amplified levels have suggested as a mediator linking the two
conditions (Despres and Lemieux 2006). Lipolysis is the process in adipose tissue
responsible for the mobilization of these NEFA into circulation and it commonly seen at
an increased level in obese patients, which can be precursor to other detrimental
metabolic syndromes (Duncan et al. 2007). Therefore, studies investigating strategies to
attenuate lipolysis and subsequent NEFA release may be an approach to treating obesityinduced type 2 diabetes. Currently, there is limited knowledge in regards to examining
the role of dietary components and their regulation of adipose lipolysis. Our lab has
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previously shown a resveratrol metabolite, piceatannol, has antilipolytic activity (Kwon,
unpublished). Thus, we hypothesized that other resveratrol metabolites may also have an
effect in in modulating lipid metabolism and play a role in reducing adipose lipolysis.
Furthermore, the objective of this study is to identify and determine the effect of different
resveratrol metabolites and their role in adipose function. Using cellular and biochemical
techniques, we examined the role of the resveratrol metabolite, TMR, in lipid metabolism,
with a focus on lipolysis and lipogenesis.

3.2

Adipose function: Lipolysis

WAT are fat stores and major energy reserves in mammals. With food intake,
NEFA are esterified to a glycerol backbone and stored as neutral lipids in the form of
TAGs and deposited in LD (Lass et al. 2011). During fasting or increased energy
expenditure, TAGs are mobilized and FA are sequentially cleaved by lipases, released,
and circulated to peripheral tissues to undergo -oxidation and generate ATP (Lass et al.
2011). This mobilization and hydrolysis of FA from the glycerol backbone is known as
lipolysis (Zechner et al. 2012). Adipocyte lipolysis occurs sequentially and is a highly
regulated process in that each step is carried out by a different lipolytic enzymes (Walther
and Farese 2012). The first FA cleaved from TAG is done by ATGL, the second is
removed by HSL, and the third by MGL resulting in three NEFA and a glycerol
backbone (Ahmadian et al. 2009).
NEFA plasma concentrations are increased in obesogenic conditions and are a
common cause for the dysregulation of lipolysis (Lafontan and Langin 2009). Currently,
there is evidence that shows impaired NEFA metabolism is a contributing factor for
insulin resistance in visceral obesity (Despres and Lemieux 2006). Increased circulating
NEFA pose a serious issue in that with excess fat accumulation and dysfunctional
metabolic state, ectopic fat disposition occurs where excess energy is stored in
undesirable locations including the heart, liver, and muscle (Despres and Lemieux 2006).
Additionally, NEFA at increased levels are thought to be a mediator linking obesity and
type 2 diabetes through -cell dysfunction, and as previously mentioned, insulin
resistance (Kahn et al. 2006). Therefore, it has been proposed that identifying
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antilipolytic agents to partially inhibit lipolysis may help to attenuate the level of
circulating NEFA, and the development of dyslipidemia and metabolic syndromes
(Langin 2006a).

3.2.1

Impact of resveratrol metabolites on lipolysis in 3T3-L1 adipocytes

As reviewed in the literature, resveratrol metabolites have varying function and
effects in different types of cells and their role is dependent on the function being
analyzed. To better understand the effects of different resveratrol metabolites, specifically
in lipolysis, several metabolites were tested on mature 3T3-L1 cells which had greater
than 90% lipid accumulation. 3T3-L1 cells were treated with resveratrol metabolites
inc  



 

 

-trans-tetrahydroxystilbene) (PIC), trans-

  

-

trimethoxy resveratrol (TMR), resveratrol-3-O-glucuronide (3G), resveratrol--Oglucuronide (4G) compared to the control vehicle, DMSO. Mature adipocytes were
incubated with serum free medium and treated in both the basal and stimulated conditions.
Incubating mature adipocytes in these two different conditions are necessary to mimic
two different physiological conditions. The basal condition imitates a resting metabolic
state in a neutrally temperate environment, or in other words, the energy that is expended
by humans at rest, in a post-absorptive state sufficient for only functioning organs. A
stimulated condition mimics a fasting condition such as after an acute exercise state
where lipolysis is induced. In this cellular model, 3T3-L1 cells were treated in both
conditions and stimulated by addition of isoproterenol (ISP) or forskolin (FSK). FSK
works to stimulate and increase accumulation of cAMP in intact cellular systems
(Seamon et al. 1981), and ISP is a -adrenergic agonist that stimulates -adrenergic
receptors and increases levels of cAMP and AMPK to promote the lipolytic pathway
(Fasshauer et al. 2002a; Minokoshi et al. 2002). Quantification of glycerol release,
normalized by protein, allowed us to see the effect of metabolite action on lipolysis. Each
metabolite was screened at a concentration of 50 µM; this is an intermediate range used
in treatment of phytochemicals (Minakawa et al. 2012) and a level that has been
previously used in our lab. Additionally, 50 µM is a frequently used with in vitro studies,
including those examining the effects of resveratrol (RES) on 3T3-L1 adipocytes (Park et
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al. 2008; Rayalam et al. 2008b). From an acute 1.5 hour treatment, PIC, TMR, and 3G
show a significant reduction in lipolysis in the basal condition compared to the control
(Figure 3.1 A). The significant inhibition of PIC on lipolysis has been demonstrated in
our lab both in vitro and in vivo (Kwon, unpublished) and is confirmed in these data. Our
new finding of the partial, significant inhibition of lipolysis by TMR and 3G in an acute,
basal treatment has not been reported. The extent at which TMR reduced the level of
lipolysis is similar to the efficacy seen with PIC. 4G demonstrated a slight reduction in
the level of glycerol release, however, it was not reduced to a significantly different level
as compared to the control. In a stimulated, acute treatment (Figure 3.1 B) we observed
significant reduction in lipolysis by PIC as well as TMR, with similar inhibition level. 4G
also significantly reduced the level of glycerol release in a lipolysis-induced environment
in contrast to a basal condition. Interestingly, we note that 3G was unable to significantly
reduce lipolysis, in this condition with an acute treatment, although we did observe a
slight reduction. Overall, we observed, as hypothesized, that other resveratrol metabolites
were able to partially inhibit lipolysis. To our knowledge, this is the first report of the
effect of different resveratrol metabolites and their effect on lipolysis with short treatment
time. Collectively, these results demonstrate the rapid action that resveratrol metabolites
have on lipolysis in mature adipocytes in vitro.
The next question addressed was the impact of these resveratrol metabolites in an
extended, chronic treatment in basal and stimulated conditions. A 24 hour treatment of
the resveratrol metabolites at 50 µM was added to mature 3T3-L1 cells with greater than
90% lipid accumulation. Compared to the control, all the metabolites examined, PIC,
TMR, 3G, and 4G demonstrated lipolysis-lowering ability in a chronic, basal
environment (Figure 3.2 A). PIC and TMR significantly reduced lipolysis at similar
levels, consistent with an acute treatment. 3G and 4G significantly diminished the
glycerol release the most. This suggests that efficacy of 3G and 4G is enhanced with a
longer treatment time. In the literature, there is one report identifying RES enhancing the
level of lipolysis through increase in free fatty acid (FFA) release in mature 3T3-L1
adipocytes (Lasa et al. 2012b). Observed by Lasa, RES significantly increased FFA in
both chronic (24 hours) basal and stimulated conditions, however, glycerol levels
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remained unchanged. Consistent with this report, RES treated for 24 hours in the basal
condition revealed no significant difference as compared to the control. However, we did
not observe the same large induction detected by Lasa (Lasa et al. 2012b). There is
greater variability observed with the chronic stimulated condition (Figure 3.2 B). Of the
treatments, PIC and TMR alone were able to reduce lipolysis significantly. We observed
similar levels between the control, 3G, and 4G. Interestingly, we observed a significant
reduction in lipolysis by RES, contrasting with reported data. However, it must be noted
that the concentration levels used in our experiment was half the dosage of that reported
induction by RES. This may be a contributor to the discrepancy between the chronic,
stimulated condition treatment of RES as well as the different lipolytic-stimulant utilized.
The distinct reduction in glycerol release correlating to the partial inhibition of
lipolysis by resveratrol metabolites is not unreasonable. Treatment with TMR
demonstrated significant reductions in both acute and chronic conditions in both basal
and stimulated conditions. This resveratrol analogue gave rise to great interest as it was
able to cause an effect in levels similar to PIC. To our knowledge, TMR has not been
studied in lipid metabolism, although it has been shown to have anti-cancer activities in a
variety of other in vitro cell systems (Dias et al. 2013; Hsieh et al. 2011b; Pan et al. 2008).
The structure of TMR, containing three methoxy groups, lends itself to be more lipophilic
and making it more favorable to be studied in a cellular adipocyte system. Although there
has been no report of resveratrol metabolites in lipolysis, 3G and 4G have been
previously studied for their delipidating effect in both maturing and mature 3T3-L1
adipocytes (Lasa et al. 2012a). It was reported that 3G was able to significantly reduce
the TAG content in mature adipocytes upon a 24 hour treatment at both 10 and 25 µM. In
comparison to a control, 3G was described as having slightly increased mRNA
expression of ATGL and HSL levels, however this increase was not significant (Lasa et al.
2012a). This previous report is consistent with our results in the chronic, stimulated
condition, where 3G shows very little action in reducing lipolysis. 4G was observed in
the same study to have action in reducing TAGs significantly both in maturing and
mature adipocytes at 25 µM. 4G also faintly increased ATGL mRNA expression and
significantly increased HSL (Lasa et al. 2012a). Like 3G, these reported findings for 4G

55
are similar to our observation in Figure 3.2 A; where there is a significant reduction in
lipolysis. RES was additionally examined in this experiment to demonstrate the structurefunction differences that occur with slight molecular modifications. Although RES has
been reported to significantly increase serum FFA in 3T3-L1 cells (Lasa et al. 2012b), it
only slightly increased FFA release in SGBS cells in the basal condition, while glycerol
levels remained unchanged in both cell lines. This is comparable to our results. Notably,
SBGS are human adipocytes, and the effect in these cells are of higher resemblance to an
actual human effect (Lasa et al. 2012b). Also, previously reported in our lab with 3T3-L1
cells, lipolysis was unaffected by RES, showing no difference from control cells in
glycerol release or FFA (Kwon, unpublished). RES has been show as most active at
reducing TAG levels (Lasa et al. 2012a), while its metabolites maintain action in other
functions; indicating that resveratrol metabolites maintain relevancy in reducing lipolysis.
In obesity, there is increased level of basal lipolysis, as previously described, and
in this system, that condition may be most similar to a chronic, stimulated condition in
our in vitro model. Therefore in looking at these results (Figure 3.2 B), we see that PIC
and TMR have the greatest potency in reducing the level of glycerol release. 3G and 4G
did not elicit the same effectiveness and there is variability seen between basal and
stimulated conditions. Additionally, 3G and 4G have already been studied in lipid
metabolism with some emphasis of their role in the lipolytic pathway. For these reasons,
we pursed the role of TMR in adipose function and studied deeper into identifying the
mechanistic pathways in which it partially inhibits lipolysis in vitro.
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Figure 3.1 Effect of resveratrol metabolites on acute release of glycerol on mature
adipocytes. Glycerol release in 3T3-L1 mature adipocytes treated for 1.5 hours at day 10
after differentiation in the presence of the vehicle (control [C]), dimethyl sulfoxide
(DMSO), or at 50 µM with piceatannol (PIC), trans-   -trimethoxyresveratrol (TMR),
resveratrol-3-O-glucuronide (3G), resveratrol--O-glucuronide (4G) in DMSO.
Comparisons between each treatment with control; subjected to basal (A) and stimulated
(B) conditions. Data are represented as means ± SEM, n=3. *, P <0.05.
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Figure 3.2 Effect of resveratrol metabolites on chronic release of glycerol on mature
adipocytes. Glycerol release in 3T3-L1 mature adipocytes treated for 24 hours at day 10
after differentiation in the presence of the vehicle (control [C]), dimethyl sulfoxide
(DMSO), or at 50 µM with resveratrol (RES), piceatannol (PIC), trans-   trimethoxyresveratrol (TMR), resveratrol-3-O-glucuronide (3G), resveratrol--Oglucuronide (4G) in DMSO. Comparisons between each treatment with control; subjected
to basal (A) and stimulated (B) conditions. Data are presented as means ± SEM, n=3. *, P
<0.05.
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3.2.2

Impact of trans-   -trimethoxyresveratrol (TMR) on cell viability

TMR has been shown to possess the capacity to inhibit cell viability as well as
stimulate apoptosis in a variety of cell systems including colon, prostate, and breast
tumors in vitro and in vivo (Dias et al. 2013; Hsieh et al. 2011a; Pan et al. 2008; Simoni
et al. 2006). Therefore, we wanted to ensure the partial inhibition of lipolysis by TMR
was not due to action inhibiting cell viability, but through other antilipolytic action. Thus,
the MTT assay was used to determine the effect of TMR in both proliferating 3T3-L1
preadipocytes along with mature adipocytes. Cells were treated with varying
concentrations of TMR (0, 5, 10, 25, and 50 µM) for 24 hours. These conditions
represent the maximum treatment concentration and time that was used in our study.
Proliferating preadipocytes showed no significant reductions in cell viability (Figure 3.3).
In fact with lower concentrations of TMR at 5 and 10 µM, we note slightly enhanced
viability. At higher concentrations of TMR, 25 and 50 µM, we did observe some slight
inhibition on viability, however these effects were not greater than 25% nor significant.
Mature adipocytes were also examined. Two day, post-confluent cells were stimulated to
differentiate with an adipogenic cocktail of DMI and grown to mature adipocytes with
lipid accumulation. At day 10 after differentiation, cells were incubated with TMR and
consistent with preadipocytes, TMR had very little effect on cell viability (Figure 3.4). At
its highest concentration, TMR maintained the same level of cell viability as the control.
Taken together, our results demonstrate that TMR does not contain cytotoxic effects in
3T3-L1 preadipocytes or mature adipocytes, and this data suggests that the reduction of
lipolysis observed is caused by an alternative pathway.
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Figure 3.3 Effect of trans-   -trimethoxyresveratrol (TMR) on 3T3-L1
proliferating cell viability. Post-confluent 3T3-L1 preadipocytes were incubated with
various concentrations of TMR for 24 hours and the viability of these cells was assessed
by MTT assay. Data are presented as means ± SEM, n=3. Not significant denoted as N.S.
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Figure 3.4 Effect of trans-   -trimethoxyresveratrol (TMR) on mature 3T3-L1
adipocyte cell viability. Mature 3T3-L1 adipocytes at day 8 after differentiation were
incubated with various concentrations of TMR for 24 hours and the viability of these
cells was assessed by MTT assay. Data are presented as means ± SEM, n=4. Not
significant denoted as N.S.
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3.2.3

TMR stability and intracellular localization

In order attribute the effects observed to TMR, a stability assay was performed to
understand its degradation pattern in DMEM media. This assay is necessary and often an
overlooked factor, with some phenolic compounds undergoing reactions with the cell
culture medium (Halliwell 2008; Long et al. 2010). Modifications in stability, chemical
structure, and interactions with other biomolecules may affect molecular targets (Delmas
et al. 2011). RES incubated in DMEM at 37oC results in some instability overtime (24
hours); however amounts of hydrogen peroxide, indicative of oxidation, were not
significant (Long et al. 2010). This demonstrates the benefit of TMR having a degree of
protection against extensive metabolism or oxidation due to its methoxylation (Lin and
Ho 2009). Currently, there is little information on the stability of resveratrol metabolites
in reference to their biological effects (Delmas et al. 2011). Resveratrol metabolite, PIC,
has been shown to be present more intact than that of RES when studied in rats
(Setoguchi et al. 2014). The pharmacokinetic profile of TMR was evaluated in rat plasma
and found to have greater plasma exposure, longer half-life and lower clearance
compared to RES, however this model was with TMR fully dissolved in hydroxypropyl-

-cyclodextrin (HP--CyD) (Lin and Ho 2009). In our in vitro model, the stability of
TMR was analyzed to ensure its efficacy. TMR was added to medium, incubated at 37oC,
and collected at different time points (Figure 3.5). The half-life of TMR, as a percentage
of the control, was determined to approximately 4 hours. Currently there are no published
data on the stability of TMR in DMEM media, the closest comparison is relatively
similar at approximately 5.8 hours seen in rat plasma dissolved in HP--CyD (Lin and
Ho 2009). Between 6 and 9 hours, TMR concentration was undermined, which suggests a
degree of degradation. However, the majority of the experiments completed in this study
were well within the range of 6 hours, with most common treatment times of 1.5 and 3
hours.
In determination of stability, we also wanted to identify where in the cell TMR
localizes. Mature 3T3-L1 cells were treated with TMR and incubated for 3 hours at 37oC.
Images of cells and accumulated lipid were captured by SRS imaging, while the
fluorescence of TMR was photographed with TPEF (Figure 3.6). The fluorescence signal
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of TMR is strong, and the green color (TMR) indicates its high intensity. These images
allow us to see that TMR co-localizes very strongly with the LD. The merged picture of
TMR and the LD demonstrate its lipophilicity and where its action may occur.
Interestingly, images taken previously by our lab show RES and in the intracellular space
of the cytosol (unpublished). Noting this, it distinctly sets apart TMR, in location and its
action in the cell may be due to its more lipophilic structure. TMR has been described as
being distributed in higher levels in major organs than in plasma and is highly likely to be
found fat tissues (Dias et al. 2013).
Collectively, although the stability of TMR in media is found in low levels after 6
hours, it is important to note that TMR is highly located with the LD within 3 hours of
treatment. This suggests that when given to the cells, much of TMR is taken up rapidly
and can have action in cellular processes, such as lipolysis, within a short period of time
in vitro.
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Figure 3.5 Stability of trans-   -trimethoxyresveratrol (TMR) in DMEM media.
TMR was added to serum free media at 50 µM and incubated at 37 C. Aliquots were
collected at various incubation time points. Samples were quantified by fluorescence at
300 nm. Data are presented as relative TMR present as a percent at time 0 hour.
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Figure 3.6 Trans-   -trimethoxyresveratrol (TMR) intracellular localization in
adipocyte. 3T3-L1 mature adipocytes treated for 3 hours at day 11 after differentiation in
serum free DMEM media in the presence or absence of TMR (0 and 50 µM). Mature
adipocytes were subjected to SRS imaging to visualize lipid droplet accumulation (red
color) and TPEF imaging to observe intracellular TMR (green color). Image dimensions
100µm x 100µm. Representative data shown; multiple images demonstrated similar
results.
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3.2.4

Dose-dependent effect of TMR on lipolysis in mature adipocytes

TMR has been studied as an anti-cancer agent; however, its role in lipid
metabolism has not yet been investigated. Here we elucidate its impact on 3T3-L1 mature
adipocyte lipolysis and its underlying molecular mechanism. In order to achieve this,
fully differentiated cells were treated at day 10 in the presence or absence of TMR at
increasing concentrations. Based on MTT assay, each concentration up to 50 µM is nontoxic and maintains no adverse effects on cell viability. Treatment of cells was done
acutely at 1.5 hours. This is based on previous results which indicated TMR had a
significant effect with a low treatment time. TMR was administered to cells at 0, 5, 10, 25,
and 50 µM in both the basal and stimulated condition (Figure 3.7 A and B). In both
conditions, TMR demonstrates significant, partial inhibition of lipolysis observed with
reduced levels of glycerol released. This reduction in lipolysis is seen at each
concentration of TMR. The efficacy of TMR and other resveratrol metabolites have been
reported to show effects even at low concentrations (Hsieh et al. 2011a; Lasa et al.
2012a). Identifying a low concentration threshold with adequate efficacy is critical for
making animal and human physiological comparisons for dosage. Furthermore,
identifying this dose-dependent response in glycerol release indicates another model
system in which the resveratrol analogue, TMR, has action.
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Figure 3.7 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
release of glycerol on mature adipocytes. Glycerol release in 3T3-L1 mature adipocytes
treated for 1.5 hours at day 10 after differentiation in the presence or absence of TMR (0,
5, 10, 25, and 50 µM). Comparisons between each treatment with control; subjected to
basal (A) and stimulated (B) conditions. Data are represented as means ± SEM, n=4. *, P
<0.001.
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3.2.5

Time-dependent impact of TMR on lipolysis in mature adipocytes

In order to understand the difference between an acute and chronic treatment, we
turned our attention to the aspect of time and the role it plays in affecting lipolysis
inhibition by TMR. Most treatments of RES and its metabolites on 3T3-L1 cells were
done a longer treatment times; a 24 hour treatment in mature adipocytes or treatment was
given every 48 hours in maturing adipocytes (Lasa et al. 2012a; Lasa et al. 2012b). In one
report by Lasa, were cells treated for a shorter, 12 hour time period with RES. As
mentioned in the literature review, the lipolysis process, though a simplistic idea, it is a
highly regulated, complex system (Zechner et al. 2012). The cascade of events which
occur by proteins and different transcription factors may be altered in their action due to
the amount time that the cell is exposed to an antilipolytic agent. We proposed that
perhaps there is an optimal time that TMR is able to modulate the lipolysis process.
TMR demonstrated an antilipolytic effect at 25 µM in glycerol release. We treated
mature 3T3-L1 cells in the presence or absence of TMR (25 µM) for 3, 6, 21 and 24
hours (Figure 3.8). We observed that TMR has a significant reduction in the glycerol
release at an acute treatment time of 3 hours, and we also noted a significant difference at
21 hours. Additionally, we also incubated mature adipocytes with 50 µM for 1.5 and 6
hours, in both basal and stimulated conditions (Figure 3.9 A and B). Similarly, we note
that the shorter, acute treatment of TMR is most effective in partially blunting glycerol
release. These results indicate that TMR acts rapidly in influencing major components in
the lipolytic cascade.

68

Glycerol Release
(ug glycerol/ mg protein)

50
*

40
30

0 µM
20

25 µM

*

10
0
0

5

10

15
20
Time (hours)

25

30

Figure 3.8 Time-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
release of glycerol on mature adipocytes with 25 µM. Glycerol release in 3T3-L1
mature adipocytes treated at different time points (1.5, 6, 21, and 24 hours) at day 10 after
differentiation in the presence or absence of TMR (25 µM). Comparisons between each
treatment with control; subjected to a basal conditions. Data are represented as means ±
SEM, n=3. *, P <0.05.
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Figure 3.9 Time-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
release of glycerol on mature adipocytes with 50 µM. Glycerol release in 3T3-L1
mature adipocytes treated at different time points (1.5 and 6 hours) at day 10 after
differentiation in the presence or absence of TMR (50 µM). Comparisons between each
treatment with control; subjected to basal (A) and stimulated (B) conditions. Data are
represented as means ± SEM, n=3. *, P <0.05.
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3.2.6

Mechanistic effect of TMR on lipolysis in mature adipocytes

The next question we inquired involved the determination by what molecular
mechanism does TMR elicit its partial inhibition of lipolysis. Lipolysis involves three
different enzymes which work to hydrolyze LD TAGs into three FA and a glycerol
backbone (Duncan et al. 2007; Zechner et al. 2012). This catabolic process and
mobilization of NEFA into the bloodstream occurs during times of energy expenditure or
fasting (Langin 2006a). As previously described, the first enzyme which acts primary on
TAG is ATGL with activation by CGI-58, followed HSL which has high affinity to
remove the second FA on DAG, and finally MGL acts to remove the final FA from the
glycerol backbone (Ahmadian et al. 2010; Walther and Farese 2012). Formerly studied in
our lab was the action of PIC on lipolysis. It has been shown that PIC works to partially
inhibit lipolysis through protein degradation of ATGL and co-activator, CGI-58 (Figure
3.10), primarily through activation of autophagy pathway targeting ATGL and CGI-58
(Kwon, unpublished). Therefore, based on our results of PIC and TMR both inhibiting
lipolysis at similar levels, the molecular mechanisms at which they suppress lipolysis
may also be similar due to resemblance in their structure.
Immunoblot analysis of lipolytic enzymes was done with mature 3T3-L1
adipocytes that were treated in the presence or absence of TMR at varying concentrations
(0, 5, 10, 25, and 50 µM) and PIC at 50 µM was used as a positive control. Western blot
analysis was performed both in basal and stimulated conditions at an acute treatment time
of 1.5 hours (Figure 3.11). In the basal condition, there is a dose-dependent response that
mimics the effect seen in glycerol release. ATGL is observably reduced as compared to
the control with different concentrations of TMR. Not surprisingly, we see that TMR is
has greatest potency at its highest concentration of 50 µM. However, the level of ATGL
reduction is not as substantial as PIC. Based on the quantification of band intensity
(Figure 3.12 A), TMR is able to reduce ATGL protein expression by 40%, whereas PIC
reduces it greater than 80%. TMR is also shows action in reducing CGI-58 protein
expression. CGI-58 is necessary for activation and maximum stimulation of ATGL as
well as regulation of the hydrolytic protein (Lass et al. 2006). TMR activity in the
reducing CGI-58 is comparable to that of PIC, in which we see just over 50% reduced by
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TMR and approximately 80% reduced by PIC. The second major lipolytic enzyme is
HSL. Phosphorylation of HSL is the major regulator for activation of the enzyme as well
as for the translocation to the surface of the LD (Schweiger et al. 2006). HSL
phosphorylation occurs at multiple sites, but phosphorylation at serine-660 is responsible
for interfacial activation and hydrolytic action of DAG (Walther and Farese 2012).
Phosphorylation of HSL (pHSL) was also analyzed. TMR action of pHSL was
surprisingly different than PIC in the basal condition. We observed slight reduction in the
level of pHSL by TMR, whereas we see a large induction of pHSL of PIC. Overall, the
level of reduction in lipolysis by glycerol release of TMR and PIC is very similar, yet the
reduction level of ATGL and CGI-58 is greater in PIC than TMR. This discrepancy may
be due to TMRs slight action inhibiting HSL activation in an acute basal treatment.
In the acute stimulated condition, we observe a similar, more pronounced trend in
the action of TMR on lipolytic enzymes. ATGL protein expression is greatly reduced by
TMR, similar to PIC (Figure 3.11 B) at approximately 80% (Figure 3.12 B). TMR only
reduced CGI-58 by 20% as compared to the control, whereas we still observe a large
reduction by PIC. The pHSL in this condition by TMR is slightly reduced maintaining a
similar trend as seen in the basal condition. Again, this contrasts with action by PIC,
which increases pHSL. This data suggests that TMR action on lipolysis in an acute
condition is predominantly through reduction of protein expression of ATGL. However,
it is worth noting, that TMR does have small action in reducing both CGI-58 and pHSL.
The ability of TMR to interact and affect, at least in part, these major lipolytic enzymes
may be attributed to its capacity to locate with the LD. The lipolysis process is occurs at
the surface of the LD, accordingly, the catabolic enzymes are equipped with a
hydrophobic region which allows binding (Duncan et al. 2007). Advantageously, the
structure of TMR lends itself to be more lipophilic, and perhaps have greater versatility
surrounding the LD.
To further confirm that greatest effect of TMR action is seen with an acute
treatment. Immunoblot analysis was performed on mature murine 3T3-L1 adipocytes
which were treated for 3 hours in the presence or absence of TMR at 0, 25, and 50 µM
concentrations (Figure 3.13). We observed large reductions in the levels of ATGL and

72
CGI-58 protein expression (Figure 3.14). These results show the reduction of lipolytic
enzymes by TMR dose-dependently. The reductions in protein expression are similar to
the levels observed by PIC with a 1.5 hour treatment. TMR, at 50 µM was able to
effectively reduce ATGL expression by approximately 80% and CGI-58 by 70%. The
level of pHSL was also consistent with our previous results, indicting slight action in
blocking its phosphorylation. These data suggest the largest reduction of lipolytic
enzymes observed by TMR at 3 hours. For comparison, TMR was treated for 6 hours on
mature adipocytes and immunoblot analysis was done to observe its effects on enzyme
expression (Figure 3.15). Observably, we note a reduction in ATGL and CGI-58 levels.
Yet when analyzing the quantification of the band intensity, we see that the detected
effect is not as large compared to a 3 hour treatment (Figure 3.16). TMR demonstrates
reduction of ATGL protein expression by 40% and reduces CGI-58 protein level by 25%.
Conversely, we see an upregulation of pHSL as compared to the control. Importantly, the
data suggests that the most effective treatment of time of TMR is acute, at 3 hours, and
time does play a role on the level of lipolytic inhibition.
In an attempt to further our understanding of the effect of TMR on lipolytic
protein expression, we examined TMR in a basal, chronic condition. 3T3-L1 mature
adipocytes were treated with different concentrations of TMR (0, 5, 10, 25 and 50 µM)
for 24 hours and protein expression was analyzed with immunoblotting (Figure 3.17).
Our protein expression levels of cells treated with TMR as compared to the control are
reduced, however not to the same degree observed in an acute treatment of 3 hours. Here
we observe an approximately 20% reduction in ATGL protein expression by TMR only
at its highest concentration of 50 µM (Figure 3.18). PIC still maintains chronic efficacy
in its degradative action of ATGL. CGI-58 protein expression had a similar trend as
ATGL; TMR induced a slight reduction while PIC sustained its degradation (data not
shown). pHSL after a 24 hour treatment was highly increased with TMR (25 and 50 µM)
and PIC treatment with a 3-fold increase. This data suggests that there may be a
compensatory effect that occurs in a chronic treatment of TMR. And although, glycerol
release is still partially inhibited with a 24 hour treatment by TMR, within the cell only
slight reductions in ATGL and CGI-58 are seen with pHSL being upregulated to possibly
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compensate for the extended time and need for an energy substrate. Taken together, our
results demonstrate TMR acts in a similar manner as PIC and the molecular mechanism
at which TMR partially inhibits lipolysis is primarily with reduction of ATGL, with slight
inhibition action on both CGI-58 and pHSL. This effect of TMR is seen at a greater
potency in an acute treatment.
It has been reported in vivo high fat diet (HFD)-induced obesity disrupts the
controlling pathways and causes changes in lipolytic protein expression and signaling
(Gaidhu et al. 2010). In an obesogenic condition, it was noted that several key lipolytic
elements are altered; this includes upregulation of ATGL and CGI-58 and down
regulation of HSL and perilipin. This culminates in an increased level of basal lipolysis
with alterations in the molecular regulation of FA metabolism and lipolysis, leading to
increased metabolic dysfunctions (Gaidhu et al. 2010). Defects in the metabolic
regulatory system ultimately results in severe consequences, as reviewed earlier,
including increased levels of circulating NEFA and insulin resistance leading to ectopic
fat distribution (Despres and Lemieux 2006). Here we describe an in vitro system with
dietary compounds effects can help to attenuate some of the dysfunctional action in
lipolysis. Our results demonstrate an altered cellular environment that would increase the
health of a HFD-obesogenic condition. We observe reduction in glycerol release and
definitive down regulation of ATGL and CGI-58, and slight reductions in the pHSL by
TMR. This action is occurs acutely and is specific to the surface of LD, where TMR
locates. The data suggests that TMR helps to modulate the first, rate-limiting step of
lipolysis through action in reducing key lipase protein expression.
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Figure 3.11 Dose-dependent acute effect of trans-   -trimethoxyresveratrol
(TMR) on lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes
were incubated in the presence or absence of TMR at various concentrations (0, 5, 10, 25,
50 µM) or piceatannol (PIC) at 50 µM for 1.5 hours in the basal and stimulated
conditions. Cells in stimulated condition were incubated with isoproterenol (ISP). The
cells were collected and protein samples were prepared. Protein levels of ATGL, CGI-58,
and phosphorylated HSL (Ser660) in these cells were detected by immunoblot assay
using their specific antibodies and -actin as a loading control. The experiment was
repeated at least twice with similar results.
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Figure 3.12 Quantification of immunoblot [shown in Figure 3.11] Film was scanned
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S),
normalized to ban   -actin. Cells were subjected to basal (A) and stimulated
(B) conditions.
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Figure 3.13 Three hour effect of trans-   -trimethoxyresveratrol (TMR) on
lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were
incubated in the presence or absence of TMR at various concentrations (0, 25, 50 µM) for
3 hours in a basal condition. The cells were collected and protein samples were prepared.
Protein levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were
detected by immunoblot assay using their specific antibodies and -actin as a loading
control. The experiment was repeated at least twice with similar results.
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Figure 3.14 Quantification of immunoblot [shown in Figure 3.13] Film was scanned
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S),
       -actin. Cells were subjected to basal conditions.
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Figure 3.15 Six hour effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic
enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were incubated in
the presence or absence of TMR at various concentrations (0, 50 µM) for 6 hours in a
basal condition. The cells were collected and protein samples were prepared. Protein
levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were detected
by immunoblot assay using their specific antibodies and -actin as a loading control.
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Figure 3.16 Quantification of immunoblot [shown in Figure 3.15] Film was scanned
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S),
       -actin. Cells were subjected to basal conditions.
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Figure 3.17 Dose-dependent chronic effect of trans-   -trimethoxyresveratrol
(TMR) on lipolytic enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes
were incubated in the presence or absence of TMR at various concentrations (0, 5, 10, 25,
50 µM) or piceatannol (PIC) at 50 µM for 24 hours in a basal condition. The cells were
collected and protein samples were prepared. Protein levels of ATGL and phosphorylated
HSL (Ser660) in these cells were detected by immunoblot assay using their specific
antibodies and -actin as a loading control. The experiment was repeated at least twice
with similar results.
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Figure 3.18 Quantification of immunoblot [shown in Figure 3.17] Film was scanned
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S),
       -actin. Cells were subjected to basal conditions.
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3.2.7

TMR partially inhibits lipolysis in mature adipocytes via protein reduction

In order to observe and confirm the overall effect that TMR exhibits on mature
adipocytes. We treated 3T3-L1 cells in the presence or absence of TMR (0, 25, 50 µM)
for 3 hours in both a basal and stimulated condition (Figure 3.19). Here we validate
results consistent with our previous data. TMR is able to modulate lipolysis in both
conditions via reductions in protein expression of ATGL and CGI-58. To note, TMR is
highly potent in the basal condition with significant reductions of ATGL at 70% and 60 %
of CGI-58 (Figure 3.20 A). TMR also showed a slight inhibition of pHSL, consistent
with previous 3 hour treatments. In the stimulated condition, we observe that TMR is able
to reduce ATGL and CGI-58, yet the levels of reduction are not as pronounced as in the
basal state (Figure 3.20 B). We detect 25% and 35% reduction in protein expression
levels of ATGL and CGI-58, respectively. Also, pHSL was slightly increased compared
to the control. This may suggest some increased signaling or alternative route the cell is
trying to control with HSL, because although HSL mainly acts on DAG, it does maintain
affinity for hydrolyzing TAG (Duncan et al. 2007). Nonetheless, these results provide
confirmatory evidence on TMR partial inhibitory action of lipolysis through reduction of
lipolytic enzymes and its modulating specificity in lipid metabolism.
Our study proposes significant, partial inhibition of mature adipocyte lipolysis by
TMR requires a concentration up to 50 µM in vitro. Our data suggests that the
physiological condition of mature adipocytes may be more sensitive to acute exposure to
circulating levels of TMR, which exerts a beneficial function in a metabolic
dysfunctional environment. The rate of NEFA release of adipose tissue is strongly
associated with insulin resistance and type 2 diabetes (Lass et al. 2006). Therefore
identifying a potential dietary compound, such as TMR, as an antilipolytic agent, which
aids in modulating this process may be a beneficial therapeutic strategy. Given the
importance of the lipolysis process in overall energy homeostasis, it imperative to
mention that with treatment of TMR, we do not observe full inhibition of glycerol release
and protein expression. It has been reported that patients with complete deficiencies in
either ATGL or CGI-58 lead to defective lipolytic catabolism, resulting in accumulation
of neutral lipid storage and an obese phenotype (Lass et al. 2006). Moreover, the partial

85
inhibition we see with TMR is more applicable as strategy to alleviate some, but not all,
adipose lipolysis.

86

ATGL

CGI-58

pHSL
(Ser660)

-actin
TMR (M):
FSK:

-

25
-

50
-

+

25
+

50
+

Figure 3.19 Acute effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic
enzymes in 3T3-L1 mature adipocytes. 3T3-L1 mature adipocytes were incubated in
the presence or absence of TMR at various concentrations (0, 25, 50 µM) for 3 hours in
the basal and stimulated conditions. Cells in stimulated condition were incubated with
forskolin (FSK). The cells were collected and protein samples were prepared. Protein
levels of ATGL, CGI-58, and phosphorylated HSL (Ser660) in these cells were detected
by immunoblot assay using their specific antibodies and -actin as a loading control. The
experiment was repeated at least twice with similar results.
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Figure 3.20 Quantification of immunoblot [shown in Figure 3.19] Film was scanned
and protein band intensity was quantified with NIH ImageJ software (ver 1.45S),
       -actin. Cells were subjected to basal (A) and stimulated
(B) conditions. Data are presented as means ± SEM, n=2-4. *, P <0.05.
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3.2.8

Impact of TMR on lipolytic gene expression

There is large importance in understanding how specific lipolytic enzyme
manifestation is effected by dietary compounds, such as TMR. However, other regulatory
mechanisms take place in modulating the transcription and translation of specific lipases.
Therefore, in order to understand if TMR acts at these levels, relative mRNA expression
of lipolytic lipases was also analyzed (Figure 3.21). Here we observed as significant
reduction in the relative expression of ATGL, as well as with the lipid associated protein,
perilipin. We note that a treatment with TMR shows a trend of reduction in both CGI-58
and HSL expression levels. The down regulation of these genes is not surprising as it has
been previously reported that RES, shown to target ATGL, displayed upregulation in
both protein and relative mRNA expression. It was also noted, however, that RES does
not have any noticeable effect on HSL (Lasa et al. 2012b). Also reported, the resveratrol
metabolite, resveratrol-3-O-sulfate (3S), displayed a reducing trend in HSL mRNA
expression levels (Lasa et al. 2012a). Collectively, our protein analysis in combination
with our mRNA analysis of lipolytic enzymes demonstrates a profound effect of TMR
and its modulation of lipolysis. Our study observed that TMR reduced glycerol release to
similar potency as PIC. And although we show that TMR also plays a role in the
reduction of protein expression of ATGL and CGI-58, it was not seen to the same degree
as PIC. Our relative mRNA expression of lipolytic enzyme illustrates another piece of the
puzzle, suggesting TMR has some transcriptional activity regarding these enzymes.
In summary, our study including molecular imaging and biochemical analysis
provides evidence that TMR is significant in partially inhibiting mature adipocyte
lipolysis through the reduction of lipolytic enzymes, possibly via mediation of protein
degradation, and potentially having activity which acutely affects enzymatic transcription.
Our results also indicate that the structure of TMR allows its co-localization with the
hydrophobic LD and may attribute to its high activity in lipid metabolism. Collectively,
this study elicits new findings that TMR modulates lipolytic activity in murine adipocytes
in vitro and can support further investigations of therapeutic approaches for metabolic
disorders induced by obesity and metabolic syndrome.
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Figure 3.21 Effect of trans-   -trimethoxyresveratrol (TMR) on lipolytic
transcription factor expression. 3T3-L1 mature adipocytes were incubated in the
presence or absence of TMR (50 µM) for 3 hours in a basal condition. The cells were
collected on day 10 and samples were prepared and subjected to quantitative gene
expression analysis of ATGL, CGI-58, HSL, and perilipin by real-time (RT)-PCR. The
signals were normalized by -actin as an internal control. The values are displayed as
fold change compared to the control; value arbitrarily set to 1. Data are presented as
relative fold induction means ± SEM, n=3. *, P <0.05.
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3.3

Adipose function: Lipogenesis

As described in the review of the literature, during the terminal phase of
adipogenesis, genes are encoded which result in the generation of FA and TAG (Kim et
al. 2013). The process of carbon movement and series of enzymatic reactions yielding the
production of FA is known as de novo lipogenesis (Ameer et al. 2014). The formation of
TAG is also conducted by enzymes which involves a series of esterification of FA
moieties to a glycerol backbone (Farese and Walther 2009). The molecular level of gene
expression of these specific enzymes as well as adipokines secreted are tightly regulated
and increased during TAG formation (Kim et al. 2013).
Dietary and molecular control of lipogenesis may be a potential target to prevent
adipose mass increase and the development of obesity and its associated diseases. Yet,
complete inhibition of lipid accumulation in adipocytes could lead to severe negative
consequences including hypertrophy and or increased storage of TAGs in non-adipose
tissues (Kim et al. 2013). Approaches involving increasing overall energy expenditure
through increased activity of thermogenesis and fatty acid oxidation (FAO) may be an
alternative route to positively affect obesity. The molecular mechanisms involved in the
regulation of adipocyte differentiation and lipid accumulation can be widely altered by
addition of bioactive dietary compounds. Furthermore, utilizing phytochemicals as a
means to modulate obesity-preventing cellular metabolic pathways may be used as a
therapeutic strategy (Jeong et al. 2012).

3.3.1

Impact of TMR on adipocyte differentiation and lipid accumulation

TMR has been shown in other cellular system to have efficacy, acting as an anticancer agent and can induce apoptosis (Dias et al. 2013; Pan et al. 2008). However, as
reviewed in the literature, the action of phytochemicals is dependent on the function
being analyzed. Currently, resveratrol metabolites have not been extensively studied in
lipid metabolism; however, there is one report which details their role in adipogenesis
and lipid accumulation. Lasa reports that treatment of 4G and 3S on maturing 3T3-L1
cells from day 0 to day 8, results in a significant reduction of relative TAG content (Lasa
et al. 2012a). PIC has also been shown to inhibit adipogenesis through modulation of
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MCE as well as through insulin receptor-dependent insulin signaling during the early
stage of differentiation (Kwon et al. 2012). Based on our results, TMR has specific action
in adipose function, specifically lipolysis, but its role in obesity development has not yet
been elucidated. Also, because other resveratrol metabolites have demonstrated an effect
on lipid accumulation, we hypothesize that TMR may also play a role in lipogenesis. In
order to understand the function of TMR on lipid accumulation, we first examined the
effect of TMR on the differentiation process in 3T3-L1 preadipocytes. Two day postconfluent preadipocytes were treated in the presence or absence of TMR (0 and 50 µM)
and an adipogenic cocktail (DMI). Differentiating cells were treated with TMR every two
days and were collected on day 6 after differentiation and lipid accumulation was
quantified with ORO staining (Figure 3.22 A). Observably, there does not seem a
dramatic reduction in lipid accumulation by TMR. Upon further inspection, we note that
the sizes of the LDs in cells treated with TMR are slightly reduced. However,
quantification of ORO stained intracellular LD was of no significance (Figure 3.22 B).
Upon further confirmation of the effect TMR has on lipid accumulation, this experiment
was repeated, yielding a large sample size (n=24). The repetition of this experiment was
slightly contrasting with previous results we observed, in which we did see a reduction in
LD formation (data not shown). Collectively, the lipid accumulation between the control
and TMR are similar,   



 

 

development we investigated intracellular gene expression.
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3.3.2

Impact of TMR on maturing adipocyte gene expression

As mentioned in the literature review, adipogenesis is a highly regulated program
in which the cascade of transcription factors are stimulated and activated leading to
terminal differentiation and ultimately developed LD (Cornelius et al. 1994). There is
high coordination of gene expression events that occur and enhance the activity of de
novo lipogenic enzymes and increase lipid accumulation (Rosen and MacDougald 2006).
It is important to note, that although PIC and 3S have been reported to have significant
action in reducing adipogenic gene expression markers of C/

 and , other

resveratrol metabolites, 4G and 3G demonstrated no significant difference from the
control, and actually trended toward increasing these markers (Kwon et al. 2012; Lasa et
al. 2012a).
In order to investigate the trend of slightly reduced lipid accumulation in maturing
3T3-L1 adipocytes by TMR, we analyzed gene expression to understand if modulation
occurred by TMR treatment. We wanted to determine if TMR was altering different gene
expression markers during differentiation using quantitative real time RT-PCR. 3T3-L1
preadipocytes were stimulated to differentiate in the presence or absence of TMR at
varying concentrations (0, 10, 25, and 50 µM) and treated every two days until collected
on day six after differentiation. The gene expression profiles of several different
functional adipose markers are discussed below.

3.3.2.1 De novo lipogenesis
As previously discussed in the literature review, the cascade of de novo
lipogenesis involves series of reactions performed by enzymes which construct FA and
generate TAG (Farese and Walther 2009) 

        

of adipocyte differentiation for its binding to fat specific enhancers. TMR at 50 µM
showed no significant difference in mRNA expression compared to the control (Figure
3.23 A). This data is consistent with reported data of RES, 3G, and 4G in which there
was no significant change in  levels of maturing adipocytes (Lasa et al. 2012a).
FAS, the major enzyme accounting for FA biogenesis, is dose dependently, and
significantly upregulated by TMR (Figure 3.23 B). ACC is also upregulated significantly
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by the highest concentration of TMR (50 µM) indicating increased production of
malonyl-CoA to be used as substrate for FAS (Figure 2.23 C). We observed upregulation
of MGAT1 and DGAT2, but there is no significant change in SCD-1 or SREBP1c (Figure
2.23 D-G). It is interesting to observe upregulation in genes that are involved in the
production of FA and TAG synthesis, due to our previous collected data that
demonstrates no significant induction in LD accumulation. This expression of lipogenic
genes poses a thought-provoking question: how does TMR upregulate de novo
lipogenesis genes and yet the level of lipid accumulation is unchanged and trends toward
a slight reduction? To begin to answer this question, we looked at the previous report
with resveratrol metabolites and their effect on ACC and FAS. Interestingly, 3T3-L1
mature adipocytes were subjected gene expression analysis of ACC and FAS after a 24
hour treatment of 10 µM of RES, 4G, 3G and 3S (Lasa et al. 2012a). ACC levels trended
increasingly, although not significant, by RES, 3G, and 4G. The level of FAS expression
was significantly reduced by 3G, however RES demonstrated an almost 1.5 fold increase
as compared to the control (not significant). Nonetheless, the action seen by RES is
comparable to that observed by TMR. In mature adipocytes, RES significantly reduced
TAG content yet had a trending increase in gene expression levels of FAS (Lasa et al.
2012a). Although the authors do not comment on this occurrence, they did show
increased levels of ATGL expression, which could indicate that RES has a higher capacity
for energy expenditure through catabolic processes. In order to see if this is the case in
our study and to fully understand this phenomenon in regards to TMR and its effect on
maturing adipocytes, we further analyzed other gene expression markers.
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Figure 3.23 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
de novo lipogenic marker gene expression. 3T3-L1 preadipocytes were subjected to
adipocyte differentiation and an adipogenic cocktail (DMI). Cells were incubated in the
presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25,
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to
RT-
          µM), (B) FAS, (C) ACC, (D) SCD1,
(E) MGAT1, (F) DGAT2, and (G) SREBP1c were quantified and normalized with the
  
 ! "-actin. The values are displayed as fold change compared to the
control; value arbitrarily set to 1. Data are presented as relative fold induction means ±
SEM, n=3. *, P <0.05.
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3.3.2.2 Adipokines
With TMR demonstrating a role in the marked increases in the lipogenic
transcription program, we wanted to further investigate its effect on maturing adipocyte
adipokine expression. Because adipose tissue is an endocrine organ, it has the capacity to
secrete adipokines affecting metabolic pathways and energy homeostasis (Kershaw and
Flier 2004). Therefore, we looked at four different adipokine gene expression profiles in
cells treated with TMR to elucidate its potential involvement. Resistin, adiponectin, and
adipsin were significantly upregulated, while the leptin was significantly reduced (Figure
3.24 A-D). First of all, resistin expression is induced during adipocyte differentiation and
its levels are increased in diet-induced obesity and suppressed by insulin in 3T3-L1
adipocytes (Haugen et al. 2001) (Steppan et al. 2001). TMR demonstrated an increase in
resistin. Its physiological function is to help regulate glucose tolerance and act as an
adaptive response (Shojima et al. 2002). Comparatively, although in a different system,
Mercader observed a 20 hour treatment of RES in mature adipocytes reduced resistin
expression (Mercader et al. 2011). Leptin plays an important role in regulating food
intake, energy expenditure, and physiologically when leptin plasma levels are increased,
insulin secretion is inhibited (Cases et al. 2001). A reduced leptin concentration signals
initiation for a starvation response (Ahima et al. 1996). Our results indicate a slight,
significant reduction in the gene expression of leptin by TMR. This is similar to other
published data with RES, which in maturing preadipocytes significantly reduces leptin
expression (Eseberri et al. 2013) as well as rat adipocytes had reduced leptin secretion
with RES treatment (Szkudelska et al. 2009). It was also noted that reduced leptin levels
may be in part due to increased cAMP in fat cells, which could result in a parallel rise in
lipolysis (Szkudelska et al. 2009). Our data suggests that the reduction in leptin levels by
TMR may induce increased energy expenditure in the cells. Adiponectin is largely
present in healthy human plasma and significantly lowered in obese subjects (Arita et al.
1999). It is an important modulator in lipid metabolism and is known to increase insulin
sensitivity as well as increase FAO (Fasshauer et al. 2002b). TMR dose-dependently
increases adiponectin expression significantly. This induction is consistent with the effect
of other resveratrol metabolites in maturing adipocytes including 3G, 4G, and 3S
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(Eseberri et al. 2013). Finally, adipsin is found in high levels in adipose tissue and its
expression has been shown to be greatly reduced in obese mice, while increased levels
are associated with a catabolic state in normal rodents (Flier et al. 1987; White et al.
1992). TMR effectively increases the expression of adipsin in 3T3-L1 maturing
adipocytes which is consistent with an increased energy expenditure state. Collectively,
the effect of TMR on adipokine gene expression is representative of cells which have
altered lipid metabolism in that they have a higher propensity to expend energy. Taken
together, this upregulation of adipokine gene expression, specifically adiponectin and
adipsin, and down regulation of leptin possibly indicate an enhanced catabolic state
which may result in reduced lipid accumulation.
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Figure 3.24 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
adipokine gene expression. 3T3-L1 preadipocytes were subjected to adipocyte
differentiation and an adipogenic cocktail. Cells were incubated in the presence of
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM) in
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The
mRNA levels of (A) Resistin, (B) Leptin, (C) Adiponectin, and (D) Adipsin were

             -actin. Data are presented as
relative fold induction means ± SEM, n=3. *, P<0.05.
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3.3.2.3 Lipolysis
To further investigate the overall effect of TMR on maturing adipocytes, lipolytic
gene expression was analyzed to determine if catabolic processes were induced. ATGL, a
major, rate-limiting step in the lipolysis was dose-dependently and significantly increased
(Figure 3.25 A). Perilipin, a LD associated protein was also significantly increased when
treated with 50 µM TMR (Figure 3.25 B). This transcriptional regulation by TMR
demonstrates its ability to increased catabolic processes. This data represents that the
action observed is highly dependent on the function being analyzed. TMR acts to increase
energy expenditure in maturing adipocytes. Comparably, there is no report of other
resveratrol metabolites concerning lipolytic gene expression in development stage of
lipogenesis. Taken together, this data suggests that TMR modulates lipolytic transcription
in maturing adipocytes which may be contributing factor of a trend toward a lessened
lipid accumulation and size during development. Th    
many major adipose functions in the progression of the cell growth.
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Figure 3.25 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
lipogenic gene expression. 3T3-L1 preadipocytes were subjected to adipocyte
differentiation and an adipogenic cocktail. Cells were incubated in the presence of
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25 and 50 µM) in
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The
mRNA levels of (A) ATGL and (B) Perilipin (0 and 50 µM) were quantified and

           -actin. Data are presented as relative fold
induction means ± SEM, n=3. *, P<0.05.
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3.3.2.4 Mitochondrial biogenesis
TMR showed an ability to increase catabolic process transcriptional activity;
therefore we wanted to explore its effect in mitochondrial biogenesis. We identified three
genes which are highly involved in the biogenesis of the mitochondria including
mitochondrial transcription factor A (Tfam) and nuclear respiratory factors 1 (NRF1)
and 2 (NRF2) (Figure 3.26 A-C). As energy demands of the cell can change through the
process of differentiation, mitochondrial content is variable and can increase based on
different physiological conditions, including adaptive thermogenesis (Goffart and
Wiesner 2003). Although 95% of the genes required for mitochondrial biogenesis are
encoded inside the nucleus, regulation of these genes are controlled by transcriptional
mechanisms (Goffart and Wiesner 2003). Tfam activation is dependent on NRF1 and
NRF2, and is an important transcriptional activator stimulating specific mitochondrial
transcription initiation as well as mitochondrial DNA maintenance (Escriva et al. 1999).
Tfam protein controls mitochondrial DNA copy number and has been shown to be vital
for embryonic development and biogenesis (Escriva et al. 1999). TMR showed a slight,
significant increase in Tfam, supporting mitochondrial biogenesis, as well as
demonstrated significant increases in both NRF1 and NRF2. The NRFs have been
reported to activate transcription of many genes involved in respiratory chain functions as
well as regulating Tfam, translocating and activating the mitochondria and its replication
and transcription (Wu et al. 1999a). NRF1 is important for mitochondrial haem synthesis
and protein import into the mitochondria. It plays an important role in the coordination of
nuclear and mitochondrial gene expression acting as a transcriptional activator for Tfam
and in MRP endonuclease, which in required for mitochondrial DNA transcription
(Goffart and Wiesner 2003). NRF1 also is critically involved in mitochondrial integrity
and functioning (Goffart and Wiesner 2003). NRF2 binds to specific target sequences in
the promoter region of a large number of nuclear encoded mitochondrial genes (Goffart
and Wiesner 2003), and is responsible for the activity and expression of mitochondrial
subunits (Virbasius and Scarpulla 1994). Our data suggest that TMR may be involved in
altering and enhancing the coordinated expression of the genes that regulate
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mitochondrial biogenesis pathway and may effective in increasing oxidative metabolism
in maturing adipocytes in vitro.
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Figure 3.26 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
mitochondrial biogenesis marker gene expression. 3T3-L1 preadipocytes were
subjected to adipocyte differentiation and an adipogenic cocktail. Cells were incubated in
the presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25,
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to
RT-PCR. The mRNA levels of (A) Tfam, (B) NRF1, and (C) NRF2 were quantified and

           -actin. Data are presented as relative fold
induction means ± SEM, n=3. *, P<0.05.
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3.3.2.5 Fatty acid oxidation
Genetic alteration in adipocyte metabolism has global implications in overall
energy homeostasis; and increases in FAO in WAT has been suggested as a way to
reduce adiposity (Rosen and Spiegelman 2006). Since TMR showed inductions in
mitochondrial biogenesis gene expression, we proposed that it may also demonstrate
upregulation of genes involved in FAO. Our findings show that TMR significantly
increased MCAD expression, yet at its highest concentration, showed no change
compared to the control in CPT1 (Figure 3.27 A and B). Increases in CPT1 and MCAD
expression exert important effects in -oxidation due to the nature that these two proteins
act as the controlling, limiting steps in the process (Tiraby et al. 2003). Importantly,
uncoupling protein 1 (UCP1) upregulation and its activity in uncoupling cells to undergo
FAO without kinetic limitation by respiratory control (Tiraby et al. 2003). TMR was able
to increase the expression of MCAD, a rate limiting enzyme involved in mitochondrial
FAO (Mottillo et al. 2012), which is consistent with our observation of trending toward
reductions in TAG content and TMRs proposed effect to allow the cell to maintain a
higher capacity to burn energy. Yet, we did not see a similar induction with CPT1,
another rate limiting enzyme highly involved in FAO by mitochondria. It is worth noting
that an analogous phenomenon was also observed when RES was treated in mature
adipocytes (Mercader et al. 2011). Overall a reduction in TAG content was observed with
RES, yet of the two FAO genes examined, RIP 140 and CPT1-L, there was a significant
increase in only one gene expression profile, while the other showed no difference from
control. Nonetheless, our data suggests TMR directly promotes transcriptional
remodeling in maturing adipocytes and trends toward increasing oxidative metabolism.
Regulation of gene expression of

-cocactivator-   - and UCP1 have

potential to increase the capacity of FAO (Tiraby et al. 2003). TMR may have activity in
increasing the expression and activation of PGC- in adipocytes, which then could
contribute to UCP1 expression induction and increase FAO, resulting in reduced fat mass.
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Figure 3.27 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
fatty acid oxidation (FAO) marker gene expression. 3T3-L1 preadipocytes were
subjected to adipocyte differentiation and an adipogenic cocktail. Cells were incubated in
the presence of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25,
and 50 µM) in DMSO for 6 days. The cellular total RNA was extracted and subjected to
RT-PCR. The mRNA levels of (A) MCAD and (B) CPT1 were quantified and
normalized with the house ke  -actin. Data are presented as relative fold
induction means ± SEM, n=3. *, P<0.05.
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3.3.2.6 Thermogenesis
The impact of TMR gives evidence that is complicatedly involved in altering the
normal functions of the cell. To gain more insight as to what is happening
transcriptionally, we analyzed thermogenic marker gene expression in these cells. TMR
significantly increases both UCP-1 and PGC-  (Figure 3.28 A and B). UCP1 is highly
abundant in the mitochondria of BAT and when activated has the ability to short circuit
the electrochemical gradient driving ATP synthesis, and consequently stimulates
respiratory chain action (Harms and Seale 2013). UCP1 biosynthesis is highly regulated
at the transcription level, and increases cAMP, a primary trigger of UCP1 (Ricquier
2011). It has been known that WAT can contain cells which express increased levels of
UCP and have the ability to take on multi-locular characteristics and pathways which
promote increased cAMP levels (Wu et al. 2012). Our data shows that treatment of TMR
increases UCP1 expression, suggesting that it may play a role in increasing the
thermogenic capacity of the cell. In coordination with this increase in UCP1, we also
observed an increase in PGC- . PGC-  is seen at high levels in BAT and can also be
induced upon cold exposure or stimulated -adrenergic pathways (Rosen and Spiegelman
2006). In WAT, PGC- 



          

 

including mitochondrial biogenesis and UCP1 action (Rosen and Spiegelman 2006).
PGC-    

                  

mitochondrial biogenesis in many cells types. It is a central transcription effector
inducing adrenergic action and thermogenesis in adipocytes (Harms and Seale 2013).
Presently, there has been indirect evidence that WAT adipocytes can acquire brown
adipocyte characteristics during conditions of cold exposure or catecholamine excess
(Rosen and MacDougald 2006). Taken together, with increases in both UCP1 and PGC transcription by TMR, this suggests that it may play an important role in increasing
the cells capacity for energy expenditure. Our data showing the upregulation of
mitochondrial biogenesis genes is consistent with our observation in the upregulation of
PGC-  by TMR. It has been reported that PGC-  stimulates a large induction in NRF1
and NRF2 expression (Wu et al. 1999a). TMR may affect the thermogenic program
causing induction of thermogenic genes, possible through the activation of -adrenergic
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signaling pathway which leads to upregulation of PGC-  and other thermogenic
expression in the maturing adipocytes. This higher capacity to utilize energy may be the
cause our observation in lipid accumulation. It is of interest to note that in mature 3T3-L1
cells, RES has been shown to increase PGC-  gene expression (Lasa et al. 2012a).
Resveratrol metabolites, 3G and 4G also increased PGC-  expression, however not in
significant levels. Collectively, action of thermogenic gene expression may be a potential
target to this class of phytochemicals.
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Figure 3.28 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
thermogenic marker gene expression. 3T3-L1 preadipocytes were subjected to
adipocyte differentiation and an adipogenic cocktail. Cells were incubated in the presence
of dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM)
in DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR.
The mRNA levels of (A) UCP1 and (B) PGC-1 were quantified and normalized with the

    -actin. Data are presented as relative fold induction means ± SEM,
n=3. *, P<0.05.
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3.3.2.7 Beige fat markers
The development of beige fat, is described as WAT having multi-locular LD
morphology, high mitochondrial content, and increased expression of specific brown fat
genes, including UCP1 and PGC-  (Harms and Seale 2013). Beige fat cells also have
increased ability for thermogenesis. Gene expression of beige-selective gens can help to
differentiate beige fat cells, from those of BAT and WAT (Wu et al. 2012). Among these
beige fat markers include transcription factors T-box 1 (Tbx1), transmembrane protein 26
(Tmem26), and PRD1-BF-RIZ1 homologues domain-containing protein-16 (Prdm16)
(Rosen and Spiegelman 2014). In order to observe any effect by TMR on the induction of
these specific beige fat markers, we examined their gene expression. Overall we not that
TMR has a variable effect (Figure 3.29 A-C). There is a significant induction of Tbx1
expression by TMR, yet the opposite effect on Tmem26, showing a significant reduction.
TMR shows no significant difference in the expression Prdm16, however it trends toward
increasing. T-box genes are essential for the developmental process and has been
identified as an enriched beige fat marker (Chapman et al. 1996; Harms and Seale 2013).
With increases in Tbx1, this suggests that TMR may have the ability to induce alterations
in the cell to increase genes with a phenotype more closely related to beige cells. Tmem26
is another enriched beige fat marker which is commonly expressed higher in inguinal fat
compared to brown fat (Wu et al. 2012). Tbx1 and Tmem26 are both beige markers which
have also been suggested to be present in classical brown tissues. Interestingly, TMR
showed a reduction in Tmem26, contrasting from a large increase in Tbx1. Currently, the
determinant of white and brown adipocyte gene programs are not completely understood,
although analysis of beige fat cells have shown a distinction between the two (Villanueva
et al. 2013; Wu et al. 2012). Therefore, we tested a third gene that is a key transcription
factor for both brown and beige fat. Prdm16 ectopic expression is known to convert
white fat precursors into thermogenic adipocytes which contain UCP1(Harms and Seale
2013). It has been identified as a co-regulator in differentiation of brown and beige cells,
with increased expression leading to beige adipocyte development and suppression of
metabolic disease (Harms et al. 2014). To note, based on the metabolic rate of BAT in
mice, is was calculated that 40-50 grams of BAT could account for 20% of daily energy
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expenditure (Rosen and Spiegelman 2014). Although our data shows no significant
alteration in Prdm16 gene expression, it trends toward increasing with TMR; coupled
with increased expression of UCP1 may suggest an altered adipocyte metabolism with
distinctive changes in physiological functions. Taken together, treatment of TMR may
induce transcriptional cell remodeling in the metabolic efficiency of energy expenditure
through a higher capacity to burn fat (Figure 3.30). Although more analysis is needed,
there may be therapeutic potential with TMR due to its involvement of induction of
thermogenic genes.
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Figure 3.29 Dose-dependent effect of trans-   -trimethoxyresveratrol (TMR) on
beige fat marker gene expression. 3T3-L1 preadipocytes were subjected to adipocyte
differentiation and an adipogenic cocktail. Cells were incubated in the presence of
dimethyl sulfoxide (DMSO) or various concentrations of TMR (0, 10, 25, and 50 µM) in
DMSO for 6 days. The cellular total RNA was extracted and subjected to RT-PCR. The
mRNA levels of (A) Tbx1, (B) Tmem26 and (C) Prdm16 were quantified and normalized
  
    -actin. Data are presented as relative fold induction means
± SEM, n=3. *, P<0.05.
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3.4

Summary and conclusions

The major objectives of this study were to identify the effect of different resveratrol
metabolites in adipose function in vitro. Due to the fact that RES is quickly metabolized
in the body, biological activities of its metabolites may be more physiologically relevant
to study (Lasa et al. 2012a). We singled out TMR as a resveratrol metabolite and
analogue having specific action in lipid metabolism, specifically for its action in
adipocyte lipolysis and lipogenesis. Our results demonstrate the first identification of
TMR acting as an antilipolytic agent in mature adipocytes as well as having action in the
development of maturing adipocytes. In our study, we were able to establish TMRs
efficacy with significant, partial inhibition of glycerol release in mature adipocytes, with
action greater than other resveratrol metabolites examined. TMR was shown to have noncytotoxic effects over a range of concentrations extending to safe usage at 50 µM
displayed by cell viability assays in both pre- and mature adipocytes. Also taken into
consideration was the stability of TMR in the medium of treated cells. Additionally, we
determined TMRs rapid uptake into the cell and co-localization with the LD, attributing
this to TMRs structure and methoxylation, providing a degree of protection and
enhancing transportation to the cell (Dias et al. 2013). Further studies are needed to fully
understand the scope of the location of TMR in the cell, but our imaging data provides
preliminary evidence.
TMR was able to significantly reduce glycerol release in mature adipocytes in both
an acute and chronic exposure. Previous research in lab demonstrated a resveratrol
metabolite, PIC, was able to significantly degrade a primary lipolytic enzyme, ATGL,
and its co-activator CGI-58 mechanistically through autophagy (intracellular degradation
of components via lysosome) (Kwon, unpublished). Due to the structural similarity of
TMR and PIC, we hypothesized that TMR action in lipolysis is also similar. TMR
demonstrated reduction in protein expression of both ATGL and CGI-58 with acute
treatment, and to a less extent with a chronic treatment. TMR also demonstrated action in
slightly blocking the activation of HSL through a slight reduction in phosphorylation. We
discovered TMRs action in the lipolysis process was greatest seen with an acute
treatment time with greatest potency with a three hour treatment in basal and stimulated
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conditions. TMR alters lipolytic gene expression of mature adipocytes which may also be
a contributor to the reduction in glycerol release and lipolysis. Overall, our data suggests
that treatment of TMR has the ability to acutely, partially inhibit lipolysis in mature
adipocytes via possible transcriptional regulation, potential mediation of protein
degradation or a combination of both. Importantly, treatment of TMR may be a
therapeutic approach to reduce the level of circulating NEFA in an obesogenic condition
and help to attenuate the induction of obesity induced insulin resistance and type 2
diabetes. Additionally, the identification of a dietary antilipolytic compound may also
help to attenuate the effects of cancer cachexia.
In an effort to further examine the role of TMR in adipose function, we also studied
its effect in the development of maturing adipocytes and lipogenesis. Our study suggests
a role of TMR in lipogenesis and cellular events in early adipocyte development. We
observed a slight trend toward reduction in LD formation. This data suggests that TMR
influences the lipogenic pathway and may primarily working through transcriptional
regulation during differentiation and development of maturing adipocytes. Interestingly,
TMR increased lipogenic gene expression, although no differences were seen compared
to the control in lipid accumulation. Further analysis of cellular gene expression showed
transcriptional increases in catabolic processes and mitochondrial biogenesis. TMR
significantly upregulates the expression of thermogenic genes, UCP1 and PCG- ,
suggesting an increased capacity for energy expenditure and thermogenesis. Taken
together, the TMR may play a significant role in transcriptional regulation during
adipocyte development and may be responsible for redirecting cellular processes toward
activating energy expenditure in maturing adipocytes. The trend towards reduced lipid
accumulation and increased lipogenic gene expression can possibly be connected through
TMRs ability to maintain balance within cellular pathways between energy storage and
utilization.
This work in identifying the effect of TMR in maturing preadipocytes may be
therapeutically important because this type of cell plays a role in obesity development.
Accordingly, during child development and adolescence, obesity mainly stems from
induction of hyperplasia, which is suggestive to the differentiation of preadipocytes into

115
mature adipocytes (Eseberri et al. 2013). Furthermore, understanding mechanisms to
prevent or reduce obesity development may be a strategy to combat this complicated
disease. Conversely, in adulthood, obesity is primarily of as result of hypertrophy of
mature adipocytes. Therefore deeper investigations into the effects on mature adipocyte
by phytochemicals are needed for the prevention of obesity and associated metabolic
diseases. A schematic diagram of our proposed mechanism is shown in Figure 3.31 and
3.32.
Our study is of significance because it illuminates the role and potential that
stilbenes can have in overall energy homeostasis. This study suggests the possible role of
TMR remodeling in adipose tissue to more metabolically active cells. It also provides
evidence utilizing dietary compounds in modulating adipose lipolysis. Our data
represents novel suggestions and potential for phytochemicals and their possible
applications in adipocyte biology. In turn, finding ways to promote the health and welling
being, especially in an obesogenic diseased state, may lessen the burden of this
preventable epidemic.
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Figure 3.30 Summary of trans-   -trimethoxyresveratrol (TMR) on functional
adipocyte gene expression. 3T3-L1 preadipocytes were subjected to adipocyte
differentiation and an adipogenic cocktail. Cells were incubated in the presence of
dimethyl sulfoxide (DMSO) or TMR (0 and 50 µM) in DMSO for 6 days. The cellular
total RNA was extracted and subjected to RT-PCR. The mRNA levels of (A) de novo
lipogenesis and adipokine marker genes, (B) lipogenic, mitochondrial biogenesis, fatty
acid oxidation, and thermogenic genes, and (C) beige fat marker genes were quantified
           -actin. Data are presented as relative fold
and 
induction means ± SEM, n=3. *, P<0.05.
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Mature adipocyte

Figure 3.31 TMR action in mature adipocyte in vitro. Acute treatment of TMR in
mature adipocyte results in reduction of protein expression and overall reduction in
glycerol release. TMR action in the cell suggests modulation of lipolytic enzymes and the
lipolysis process.
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Maturing adipocyte

Figure 3.32 TMR action in development of maturing adipocyte in vitro. Changes
induced by treatment of TMR in maturing adipocyte during lipogenesis. mRNA
expression profiles are altered by TMR during development, suggestive of
transcriptional remodeling and potential balance between energy utilization and storage
by cell.
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CHAPTER 4. FUTURE WORK

4.1

Limitations of study

Chapter 3 outlines our results and demonstrates the significant, partial inhibition of
lipolysis by an acute treatment of TMR. It also shows the effect of TMR in the
development of maturing adipocytes and the transcriptional remodeling of the adipocyte
toward increased energy expenditure. However, there are some limitations to the study
that are important to consider:
Firstly, the data collected from our experiments were entirely based on in vitro
results. The 3T3-L1 preadipocyte cell line is widely established, however, due to the fact
that the results in this study are trying to mimic actual physiological conditions of human
obesity, the role of prevention, development, and associated metabolic disorders;
understanding the effect of dietary compounds in vivo is critical. Additionally, our
experiments were conducted in a tightly controlled atmosphere with one type of cell. To
be able to have more substantial evidence, a more complex and intricate model such as an
animal in vivo system, is needed to translate the effects to humans.
Our study also had technical limitations. Our data in regards to the inhibition of
lipolysis was done primarily through the level of glycerol release. To further confirm our
findings, a free fatty acid assay and measurement of TAG, DAG, and MAGs levels
should also be completed which would account for specific steps in lipolysis that were
effected. Our study utilized protein expression and analysis to determine the relative level
of activity in the cell, whereas biochemical enzyme assays to measure the actual activity
of the enzymes would allow greater specificity in determining the modulation in the cell.
Furthermore, these types of assays done in primary murine and human adipocytes would
also strengthen our data, as well as demonstrate reproducibility and reliability.
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The lipogenesis piece of our study is restricted to only mRNA gene expression
analysis and technically limited. Additional confirmatory data with replication and
reproducibility of the effects we observed will help to strengthen our gene expression
analysis results. Furthermore, biochemical measurement of the correlating protein levels
and enzymatic activity of the genes we observed changes in is critical to the proposed
effect induced transcriptionally by TMR. Other technical assays including mitochondrial
biogenesis and ATP production techniques would also help connect the data observed in
the gene profiling and aid to substantiate TMRs effect.
Mechanistic pathways are a large part in identifying the beneficial effect of
phytochemicals. In regards to TMRs effect in lipogenesis, this is a limitation of our study.
Our data lacks knowledge on specific pathways and how those pathways may be directly
altered by TMR. One technique in identifying changes in lipogenesis is the utilization of
radioisotope labeling to track changes in the biosynthesis of TAGs. In addition, SRS
imaging with labeled glucose is another method that allows the visualization of the
source and construction of the LD.
Finally, the largest drawback of the study is the fact that the data is presented on
findings based in vitro and should be tested in an in vivo system. TMR showed efficacy at
50 µM, however this is higher than a physiological condition. Current literature is limited,
however one studied noted using 4 mg/kg with an intraperitoneal (IP) injection and 10
mg/kg via oral gavage, however this concentration was fully dissolved in a HP--CyD
(Lin and Ho 2009; Lin et al. 2010). Previous research in our lab for PIC utilized 10
mg/kg/day in an animal model. For animal treatment with TMR, a concentration range up
to approximately 10-15 mg/kg would be sufficient maximum dose. The bioavailability of
TMR needs to be considered when choosing a method of treatment. According to the
study by Lin, they analyzed the pharmacokinetic profile of TMR when given via oral
gavage and found that it has a short absorption time and prolonged elimination time, with
a calculated bioavailability F value of 54.9% (Lin and Ho 2009). Taking this into
consideration, giving the animals an IP injection would allow us to see the direct effect of
TMR and it would prevent any modifications to the compound. Oral gavage of TMR
dissolved in a vehicle would give a better understanding of the physiological relevance
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once ingested. To note, it has been suggested that food may enhance the bioavailability of
TMR, by stimulated bile secretions (Lin and Ho 2009). In an experimental model that is
identifying the health benefit of a compound in regards to prevention of obesity, it would
be most applicable to administer TMR in the diet. Because the nature of this study would
be a high fat diet-induced obesity model, the increased fat content may help to increase
the bioavailability of the compound via normal bile secretions. However, stability of
TMR in the food matrix would need to be examined to ensure its functionality is still
intact. Depending on the adipose function being analyzed, different animal models should
be employed. Specific parameters are further discussed in detail below.
The following outlines experiments and future work that should be done to better
understand the role of TMR in affecting overall energy homeostasis.

4.2

Future Work: TMR in lipolysis

Additional research is needed to fully understand mechanistically how TMR acts in
the cell specific to the lipolytic pathway. Future work needs to be completed both in vitro
and in vivo studies to characterize TMR in overall modulation of lipolysis.
Further characterizations of the lipolytic enzymes involved in the lipolysis process
are needed to gain insight into the overall action of TMR. We mainly examined ATGL,
the first step in lipolysis, however HSL and MGL are still players in the overall
progression of lipolysis and their roles maintain specificity. HSL can hydrolyze both
TAG and DAG, yet it has a higher affinity for DAG (Duncan et al. 2007). We measured
the phosphorylation of HSL at serine-660; responsible for the LD interfacial activation
and hydrolysis of DAG (Walther and Farese 2012). However measuring the total level of

   

                

potential degradation or induction. Similarly, identifying the total protein expression level
of MGL and perilipin would complete the picture of TMRs modulating role in the entire,
sequential process of lipolysis. Additionally, other technical measurements need to be
explored include biochemical enzyme assays order to confirm the action of TMR.
Biochemical analysis of enzymatic activity of enzymes involved in lipolysis would give a
clear evidence to the level TMR modulates this process.
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Our results lack the knowledge and specificity of how possible enzymatic
degradation occurs: through autophagy or proteasome proteolysis. Our lab has previously
demonstrated that degradation of ATGL by PIC is not proteasome-dependent, but
dependent on autophagy and occurs through an autophagy pathway, via the use of
different inhibitors. Macroautophagy is a lysosomal degradative pathway present in cells
and is responsible for degrading cytosolic organelles and protein aggregates which are
too large for proteasome degradation. Autophagy is a highly regulated process in which
whole organelles and regions of cytoplasm are sequestered inside an enveloping doublemembrane structure termed, autophagosome, which translocates to lysosomes for fusion
and content degradation (Lee et al. 2010; Singh et al. 2009). Proteolysis involves
proteases which hydrolyze peptide bonds and then free amino acids are released
(Glickman and Ciechanover 2002). This occurs under different physiological
circumstances and allows the cell to accommodate to changes and adapt to its
environment (Ciechanover 1994; Glickman and Ciechanover 2002). TMRs apparent
reduction of ATGL and CGI-58 is done through an unknown mechanism, and identifying
how TMR works would further our knowledge of its modulation, but also increase
understanding in the markers and regulation of the machinery involved. We also
observed transcriptional changes by TMR with an acute treatment. This suggests rapid
turnover in the cell, however this would need to be confirmed through additional
biochemical analysis experiments.
The most critical future experiment is to utilize our results and correlate them into
an in vivo system. It would be advantageous to conduct primary cell culture before
entering into an in vivo study. This would be a critical step to get a more accurate picture
of how cells would respond. Testing the efficacy of TMR in both murine and human
primary cells would be supportive data before taking on an animal model. An animal
model testing TMRs effect in lipolysis would consist of approximately 16 week old male
C57B/6J mice that are obese and continued to be fed a high fat diet (60% of calories from
fat) (HFD) for 1 week prior to treatment. Due to the fact we saw that TMR is most
effective with an acute treatment, with an in vivo model, this correlates to about 2-4
weeks of treatment. Two groups (n=8) should be fed as followed: HFD and HFD + 10
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mg/kg/day TMR. In this treatment mice should have access to water and food ad libitum.
Body weight and food intake should be recorded about every 3rd day, as well as blood
samples to measure basal glycerol release, FFA, TAG, and glucose levels. Physiological
and biochemical parameters after sacrifice should be done upon collection of all tissues,
including but not limited to, histology, gene profiling, and immunoblot analysis.

4.3

Future Work: TMR in lipogenesis

We were able to observe that TMR increased catabolic and thermogenic gene
expression, however, our study was limited to only gene profiling in vitro. Further
biochemical and proteomic analysis is needed and additional focus on signaling pathways
involved in observed upregulation.
It would be beneficial to collect confirmatory data as well as test other genes
involved in lipogenesis, catabolic processes, and include gene expression that is specific
to beige fat markers. As previously described, beige cells in murine WAT are defined by
their morphology, high mitochondrial content, and expression a core set of brown fat
genes (Harms and Seale 2013). Our data lacks biochemical analysis of the effects
obtained with gene expression. Therefore, analyzing in depth a wider range of genes and
correlating proteomic analysis and utilizing enzymatic activity assays would elucidate
TMRs overall effect during the development of the cell, and would also indicate any
metabolic switch. Additionally, techniques involving mitochondrial biogenesis,
respiration, and ATP production need to be investigated to confirm our gene expression
analysis.
Further investigation in the location and effect of TMR during the development
stage of maturing adipocytes is needed. Deuterium-labeled glucose added into the
medium during the early stages of differentiation and photographed with SRS imaging
would allow us to visualize the progression of lipid droplet formation and the source of
energy utilized. This assay would give us a better understanding of how TMR is
influencing cell during growth and de novo lipogenesis. Additionally, radioisotope
labeling of FA is another technique that would allow detection of direct pathway changes.
Increased characterization of TMR is needed by these types of methods to better
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            ulating, which is critical to
knowledge of its therapeutic potential.
Analyzing the effect of TMR in vivo is imperative. Investigating the remodeling
role of TMR in vivo would be more applicable for interpretation of physiological
conditions and human comparison. Examining the role of TMR treatment during the
development of young mice in a HFD-obesity-induced model, would allow us to
critically analyze its effect. 3 week old male C57B/6J mice with three groups (n=8) fed as
HFD, HFD + low dose (3 mg/kg/day TMR), and HFD + high dose (15 mg/kg/day TMR).
During the experimental period, mice should have access to water and food ad libitum.
Body weight and food intake will be measured every 3 days with all groups followed for
approximately 4-6 weeks, around when potential weight diverges are seen for at least 1
week. If significant change in body weight does not occur, dosages may need to be
adjusted. Fecal samples will be collected for 1 week and respiratory exchange ratio will
be analyzed. To determine a potential energy expenditure changes and increased health of
adipose tissue of TMR, specific biochemical parameters associated with obesity
development should be measured including serum indicators, gene profiles, and protein
expression levels in different tissues to show the critical impact on adipogenesis and
lipogenesis. Other tests should be completed not exclusive to glucose tolerance test,
serum levels of triglyceride, glucose, insulin, glycerol, and FFA. Additionally, adipose
tissue, liver, kidney, intestines and other major tissues should be collected, weighed with
histology, PCR, and immunoblot analysis measured along with other biochemical
analysis, and measurements specific to mitochondrial biogenesis and thermogenesis.
Mitochondrial uncoupling has been associated as means of weight-loss therapy and
increasing the activity of either brown fat, beige fat, or both has large potential for the
treatment of obesity and metabolic disease by dietary compounds (Harms and Seale
2013). This model would be representative of a therapeutic treatment during adolescent
development and growth, in which we could identify any alteration in overall energy
balance and changes in homeostasis.
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4.4

Conclusion

Collectively, our study elucidates the beneficial activities of dietary compounds,
such as TMR, in the context of adipose function. Our data represents foundational work
that can be expanded through future studies, including further investigations not
mentioned and those mentioned above. In the future, additional in vivo models will help
to gain new insights into the potential, therapeutic application of TMR and other
resveratrol metabolites in adipose biology. The over-arching big picture is that this type
of research can help people who suffer from a variety of metabolic disorders. Identifying
ways to improve overall health and well-being can improve quality of life and increase
longevity. The use of phytochemicals as a means to treat conditions has been around for
centuries, as stated by Hipp   

     



This idea of food components as a means to improve health is fundamental and needs
further investigation in discovering the specific pathways and their impact on energy
balance. A focus on lipid metabolism is extremely relevant to the current health status
America and application of functional food components may be key. Overall, there is
vast potential for investigation of dietary components to help reduce the incidence of
obesity and attenuate its associated metabolic disorders.
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